Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No. )


Boston Scientific Corporation
(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
ý	No fee required.
o	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
	(1)	Title of each class of securities to which transaction applies:
	(2)	Aggregate number of securities to which transaction applies:
	(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
	(4)	Proposed maximum aggregate value of transaction:
	(5)	Total fee paid:
o	Fee paid previously with preliminary materials.
o	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
	(1)	Amount Previously Paid:
	(2)	Form, Schedule or Registration Statement No.:
	(3)	Filing Party:
	(4)	Date Filed:

You are cordially invited to attend the Annual Meeting of Stockholders (Annual Meeting) of Boston Scientific Corporation (the Company) to be held on Thursday, May 6, 2021, at 8:00 a.m. Eastern Time. In light of the ongoing public health crisis caused by the COVID-19 pandemic, the Annual Meeting will be held in a virtual format only, via live webcast over the internet. You will be able to join the Annual Meeting and vote and submit your questions online during the Annual Meeting by visiting https://www.virtualshareholdermeeting.com/BSX2021. We have designed the virtual Annual Meeting to ensure that stockholders are afforded the same opportunity to participate as they would have at an in-person meeting, including the right to vote and ask questions through the virtual meeting platform. Reference to "in person" attendance or voting in our proxy materials refers, therefore, to attending or voting at the Annual Meeting virtually.

These matters are more fully described in the accompanying Notice of Annual Meeting and Proxy Statement. Our Board of Directors urges you to read the accompanying Proxy Statement and recommends that you vote "FOR" all of the director nominees, the named executive officer compensation, and the ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm and "AGAINST" the stockholder proposal described in this Proxy Statement. At the meeting, you will be provided with the opportunity to ask questions.

On or about March 24, 2021, we will mail to our stockholders of record at the close of business on Friday, March 12, 2021, the record date for our Annual Meeting, an Important Notice of Internet Availability of Proxy Materials (Notice) containing instructions on how to access our Proxy Statement and Annual Report for the year ended December 31, 2020 (Annual Report) on the Internet and also how to vote their shares via the Internet. If you received a Notice by mail, you will not receive printed proxy materials unless you specifically request them. Both the Notice and the Proxy Statement contain instructions on how you can request a paper copy of the Proxy Statement and Annual Report.

The Board of Directors appreciates and encourages stockholder participation in the Company's affairs. Whether or not you plan to virtually attend the Annual Meeting, we encourage you to vote your shares. Accordingly, we request that as soon as possible, you vote via the Internet or, if you have received printed proxy materials, you vote via the Internet, by telephone or by mailing your completed proxy card or voter instruction form.

Michael F. Mahoney
Chairman of the Board of Directors
President and Chief Executive Officer

The Annual Meeting of Stockholders of Boston Scientific Corporation (Annual Meeting) will be held on Thursday, May 6, 2021, at 8:00 a.m. Eastern Time. In light of the ongoing public health crisis caused by the COVID-19 pandemic, the Annual Meeting will be held in a virtual format only, via live webcast over the internet. You will be able to join the Annual Meeting and vote and submit your questions online during the Annual Meeting by visiting https://www.virtualshareholdermeeting.com/BSX2021. We have designed the virtual Annual Meeting to ensure that stockholders are afforded the same opportunity to participate as they would have at an in-person meeting, including the right to vote and ask questions through the virtual meeting platform. Reference to "in person" attendance or voting in our proxy materials refers, therefore, to attending or voting at the Annual Meeting virtually. The Annual Meeting will take place for the following purposes:

Only stockholders of record at the close of business on Friday, March 12, 2021, are entitled to notice of and to vote at the meeting or any adjournments or postponements thereof.

It is important that your shares be represented and voted at the Annual Meeting. Whether or not you plan to attend the Annual Meeting in person, we encourage you to submit your proxy as soon as possible. For specific instructions, please refer to your Important Notice of Internet Availability of Proxy Materials or to the question on page 9 of the accompanying Proxy Statement entitled "How do I vote by proxy?"

At this meeting, stockholders will be asked to elect nine nominees for director, approve, on a non-binding, advisory basis, named executive officer compensation, ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the 2021 fiscal year, and consider and vote upon a stockholder proposal described in this Proxy Statement, if properly presented at the Annual Meeting. Management will also respond to questions from stockholders. Our principal executive offices are located at 300 Boston Scientific Way, Marlborough, Massachusetts 01752, and our telephone number is (508) 683-4000. When used in this Proxy Statement, the terms "we," "us," "our," "Boston Scientific" and "the Company" mean Boston Scientific Corporation and its businesses and subsidiaries.

In connection with its solicitation of proxies for use at our Annual Meeting, our Board of Directors (Board) (i) has made these materials available to you via the Internet or, upon your request, via email, or (ii) upon your request, has delivered or will deliver printed versions of these materials to you by mail. As a stockholder of record of our common stock at the close of business on March 12, 2021, the record date for our Annual Meeting, you are invited to attend the virtual Annual Meeting, and are entitled to and requested to vote on the items of business described in this Proxy Statement.

We believe that a virtual meeting will provide expanded stockholder access and participation, improved communications, as well as additional safeguards for health and safety in light of

developments related to COVID-19. You will be able to join the Annual Meeting and vote and submit questions online during the Annual Meeting by visiting https://www.virtualshareholdermeeting.com/BSX2021 and using the 16-digit control number included on the Important Notice of Internet Availability of Proxy Materials (Notice), on your proxy card, or on your voting instruction form provided by your broker, bank or other nominee. Online check-in will be available at the virtual meeting site approximately 15 minutes prior to the beginning of the Annual Meeting.

Why did I receive a notice in the mail regarding the Internet availability of proxy materials instead of a full set of printed proxy materials?

Pursuant to rules adopted by the Securities and Exchange Commission (SEC), we are making this Proxy Statement and our Annual Report for the year ended December 31, 2020 (Annual Report and, together with this Proxy Statement, the proxy materials) available to stockholders electronically via the Internet. Stockholders will be able to access the proxy materials on the website referred to in the Notice or request to receive printed copies of the proxy materials and a proxy card. Instructions on how to access the proxy materials via the Internet or to request a printed copy may be found in the Notice and in this Proxy Statement. We believe that this electronic process expedites your receipt of the proxy materials and reduces the cost and environmental impact of printing proxy materials for our Annual Meeting.

On or about March 24, 2021, stockholders of record and beneficial owners of our common stock at the close of business on March 12, 2021 will be sent a Notice instructing them as to how to receive their proxy materials via the Internet. The proxy materials will be available on the Internet as of March 24, 2021.

Beginning March 24, 2021, you can access the proxy materials and vote your shares online at www.proxyvote.com. The proxy materials are also available on our own website (www.bostonscientific.com).

If you prefer to receive paper copies of the proxy materials and a proxy card, you may still do so. You may request printed materials by (i) calling (800) 579-1639; (ii) sending an email to sendmaterial@proxyvote.com; or (iii) logging onto www.proxyvote.com using the credentials provided on your Notice or proxy card.

Stockholders who held shares of our common stock at the close of business on Friday, March 12, 2021, are entitled to vote at the Annual Meeting. Each share of our common stock is entitled to one vote.

How many shares are eligible to be voted and how many shares are required to hold the Annual Meeting?

A quorum is required to hold the Annual Meeting and conduct business. The presence at the Annual Meeting, in person or by proxy, of stockholders holding a majority of our common stock outstanding as of the close of business on Friday, March 12, 2021, the record date, will constitute a quorum for

purposes of holding and conducting business at the Annual Meeting. As of March 12, 2021, we had 1,420,516,801 shares of our common stock outstanding — each entitled to one vote at the Annual Meeting — meaning that 710,258,401 shares of common stock must be represented in person or by proxy to have a quorum. Our common stock is our only outstanding class of voting securities. For purposes of determining whether a quorum exists, broker non-votes (as described further below) and proxies received but marked "ABSTAIN" will be counted.

Your vote is very important. Whether or not you plan to attend the virtual Annual Meeting, you may give a proxy to be voted at the Annual Meeting either:

If you vote by mail, no postage is required if your proxy card is mailed in the United States. If you properly vote pursuant to the instructions provided in the Notice or properly complete and deliver your proxy card (whether electronically, by mail or by telephone) and our Inspector of Election receives your instructions in time to vote at the Annual Meeting, your "proxy" (one of the individuals

named on your proxy card) will vote your shares as you have directed. If you sign and return your proxy card, but do not make specific selections, your proxy will vote your shares as recommended by the Board. If any other matter is properly presented at the Annual Meeting, including a proposal to postpone or adjourn the meeting, your proxy will vote your shares in accordance with his or her discretion. At present, the Board knows of no other business that is intended to be brought before or acted upon at the Annual Meeting.

What if I need assistance with voting or have questions regarding the Annual Meeting?

If you need assistance with the voting of your shares or have questions regarding the Annual Meeting, please contact our proxy solicitation advisor:

Alliance Advisors, LLC
200 Broadacres Drive, 3rd Floor
Bloomfield, NJ 07003
(844) 866-9429 (Toll Free in the United States)

If you have technical difficulties accessing or using the virtual meeting site during the Annual Meeting, you should call the technical support number on the virtual meeting site. The virtual meeting site is supported on browsers (e.g., Internet Explorer, Firefox, Chrome and Safari) and devices (desktops, laptops, tablets and cell phones) running the most updated version of applicable software and plug-ins. Each participant should ensure strong Wi-Fi or other internet connection.

In the election of directors, your vote may be cast "FOR" one or more of the nominees or your vote may be "WITHHELD" with respect to one or more of the nominees. If you sign your proxy card with no further instructions, your shares will be voted in accordance with the recommendation of the Board.

In the advisory vote to approve named executive officer compensation, your vote may be cast "FOR" or "AGAINST" or you may "ABSTAIN." If you "ABSTAIN," it will not count as a share actually voted and will have no effect on the determination of this proposal. If you sign your proxy card with no further instructions, your shares will be voted in accordance with the recommendation of the Board.

In the ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm, your vote may be cast "FOR" or "AGAINST" or you may "ABSTAIN." If you "ABSTAIN," it will not count as a share actually voted and will have no effect on the determination of this proposal. If you sign your proxy card with no further instructions, your shares will be voted in accordance with the recommendation of the Board.

In the stockholder proposal described in this Proxy Statement, your vote may be cast "FOR" or "AGAINST" or you may "ABSTAIN." If you "ABSTAIN," it will not count as a share actually voted with respect to determining if a majority vote is obtained under our By-Laws and will have no effect on the determination of this proposal. If you sign your proxy card with no further instructions, your shares will be voted in accordance with the recommendation of the Board.

At present, the Board knows of no other matters to be presented for stockholder action at the Annual Meeting.

What is the difference between holding shares as a stockholder of record and as a beneficial owner?

Most of our stockholders hold their shares through a broker, trustee, bank, other financial intermediary or other nominee rather than directly in their own name. As summarized below, there are some differences between stockholders of record and beneficial owners.

If your shares are registered directly in your name with our transfer agent, Computershare Shareowner Services, as of the close of business on Friday, March 12, 2021, you are considered the stockholder of record with respect to those shares, and the Notice or proxy materials are being made available, electronically or otherwise, directly to you by the Company. As the stockholder of record, you have the right to grant your voting proxy directly to the Company or a third party, or to vote in person at the Annual Meeting. The Company has made available a proxy card or electronic voting means for you to use for voting purposes.

If your shares are held through a brokerage firm, trustee, bank, other financial intermediary or other nominee, as of the close of business on Friday, March 12, 2021, you are considered the beneficial owner of those shares held in street name, and the Notice or proxy materials are being made available, electronically or otherwise, by the Company to your broker, trustee, bank, other financial intermediary or other nominee (the intermediary) and they will forward these materials to you, together with a voting instruction form if furnished via paper copy to your intermediary. As the beneficial owner, you have the right to direct your intermediary on how to vote and are also invited to virtually attend the Annual Meeting; however, since you are not the stockholder of record, you may not vote these shares in person at the Annual Meeting, unless you request, complete and deliver a legal proxy from your intermediary. If you requested printed proxy materials, your intermediary will enclose a voting instruction form for you to use in directing the intermediary regarding how to vote your shares.

What discretion does my broker have to vote my shares held in "street name?"

The NYSE rules allow your broker to vote your shares in its discretion on "routine" proposals when it has not received instructions from you at least ten days prior to the Annual Meeting. The proposal regarding the ratification of the appointment of our independent registered public accounting firm is a matter considered routine under applicable rules and, therefore, your broker may vote on your behalf for this matter if you do not otherwise provide instructions. The election of directors, the advisory vote on the named executive officer compensation, and the stockholder proposal described in this Proxy Statement are not considered routine matters. If you do not instruct your broker how to vote your shares on the non-routine matters, your broker will not be permitted to vote your shares on such matters. This is referred to as a "broker non-vote."

Broker non-votes (shares held by brokers that do not have discretionary authority to vote on the matter and that have not received voting instructions from their clients) are counted for purposes of determining whether a quorum is present, but are not counted or deemed to be present, represented or voted for the purpose of determining whether stockholders have approved a proposal. A broker non-vote will have no effect on the outcome of the election of directors or the advisory vote on the named executive officer compensation.

If you participate in our 401(k) Retirement Savings Plan, as amended and restated (401(k) Plan), you will receive a single proxy card (together with the proxy materials) or Notice that covers all shares credited to your plan account(s) and shares that you own of record that are registered in the same name. If your plan account(s) are registered in different names, you will receive separate proxy cards or Notices for your record and plan holdings. You may vote your shares by following the instructions

provided in your proxy card or Notice and utilizing the credentials provided therein. Your vote will serve to instruct the trustees and fiduciaries of our 401(k) Plan how to vote any shares of our common stock held in our 401(k) Plan on your behalf. Shares of our common stock held in our 401(k) Plan must be voted on or before 11:59 p.m. Eastern Time on May 1, 2021. The trustee and fiduciaries of our 401(k) Plan will vote shares for which timely instructions are not received in the same proportion as other plan shares that were voted.

What happens if I don't specify how I want my shares voted on one or all of the proposals?

If you are the stockholder of record and you sign, date and return your proxy and do not mark how you want to vote, your proxy will be counted as a vote "FOR" all of the nominees for directors, "FOR" the named executive officer compensation, "FOR" the ratification of our independent registered public accounting firm, Ernst & Young, and "AGAINST" the stockholder proposal described in this Proxy Statement. If you hold your shares in street name, please see the discussion on "What discretion does my broker have to vote my shares held in 'street name?'," above.

Can I change my vote or revoke my proxy after I have already voted or given my proxy?

Yes. If you are a stockholder of record, you may change your vote or revoke your proxy at any time before the proxy is voted at the Annual Meeting. To change your vote, you may:

Your last dated proxy, properly completed and timely received prior to, or vote cast at, the Annual Meeting will be counted.

If you own your shares in street name, please contact your broker or other intermediary for instructions on changing your vote or revoking your proxy.

Yes. If you are the stockholder of record of the shares, you will have the opportunity to vote in person when you attend the virtual Annual Meeting online by visiting https://www.virtualshareholdermeeting.com/BSX2021. In order to vote during the Annual Meeting, you will use the 16-digit control number included on the Notice, on your proxy card, or on your voting instruction form provided by your broker, bank or other nominee. However, since a beneficial owner holding shares in street name is not the stockholder of record, if you are such a beneficial owner of shares, you may not vote your shares in person at the virtual Annual Meeting unless you obtain a legal proxy from the broker or other intermediary that holds your shares giving you the right to vote the shares at the Annual Meeting. Please provide the legal proxy information once you log into the Annual Meeting.

Broadridge has been engaged as our independent agent to tabulate stockholder votes and act as Inspector of Election for the meeting.

Proxy instructions, ballots and voting tabulations that identify individual stockholders are handled in a manner that protects your voting privacy. Your vote will not be disclosed either within the Company or to third parties, except:

Occasionally, stockholders provide written comments on their proxy cards, which may be forwarded to the Company's management and the Board.

Your proxy will still be effective and will be voted at the rescheduled Annual Meeting. You will still be able to change or revoke your proxy until it is voted, provided such new proxy or revocation is properly completed and timely received.

Our By-Laws provide that a stockholder may present business to be considered at the Annual Meeting only if proper prior written notice was timely received by us. Other than the items of business described in this Proxy Statement, our Board is not aware of any other business to be acted upon at the Annual Meeting; however, if any other business does properly come before the Annual Meeting, the persons named as proxies on the proxy card will vote your shares in accordance with their discretion.

We will report the final voting results on a Current Report on Form 8-K filed with the SEC within four business days after the Annual Meeting. The Form 8-K will be available on the SEC's website, www.sec.gov, as well as on our own website, www.bostonscientific.com, under the "Investor Relations" section.

A list of stockholders entitled to vote at the Annual Meeting will be available during the Annual Meeting and for ten days prior to the Annual Meeting, between the hours of 8:30 a.m. and 5:00 p.m. Eastern Time, at our Corporate Headquarters located at 300 Boston Scientific Way, Marlborough, Massachusetts 01752. If you would like to view the stockholder list, please contact our Corporate Secretary to schedule an appointment by calling (508) 683-4000 or writing to her at 300 Boston Scientific Way, Marlborough, Massachusetts 01752.

Under rules adopted by the SEC, we are furnishing proxy materials to our stockholders primarily via the Internet instead of mailing printed copies of those materials to each stockholder. On or about March 24, 2021, we will mail to our stockholders (other than those who previously requested electronic or paper delivery) an Important Notice of Internet Availability of Proxy Materials containing instructions on how to access our proxy materials, including our Proxy Statement and our Annual Report. The Notice also instructs stockholders on how to vote via the Internet.

This process is designed to expedite stockholders' receipt of proxy materials, lower the cost of the Annual Meeting and help conserve natural resources; however, if you would prefer to receive printed proxy materials and a proxy card, please follow the instructions included in the Notice and in this Proxy Statement. If you have previously elected to receive our proxy materials electronically, these materials will continue to be made available to you via email until you elect otherwise. If you have previously elected to receive printed proxy materials, you will continue to receive these materials and a proxy card in paper format until you elect otherwise.

This Proxy Statement contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "may," "estimate," "intend" and other similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. Factors that may cause actual results to differ materially from those contemplated by the statements in this Proxy Statement can be found in our most recent Annual Report on Form 10-K filed with the SEC and in the Quarterly Reports on Form 10-Q that we have filed or will file hereafter under the heading "Risk Factors" and "Safe Harbor for Forward-Looking Statements." The forward-looking statements speak only as of the date of this Proxy Statement and undue reliance should not be placed on these statements. We disclaim any intention or obligation to publicly update or revise any forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

This Proxy Statement contains statements regarding individual and Company performance objectives and targets. These objectives and targets are disclosed in the limited context of our compensation plans and programs and should not be understood to be statements of management's future expectations or estimates of future results or other guidance. We specifically caution investors not to apply these statements to other contexts.

Our entire Board is elected annually by our stockholders and currently consists of ten members.

On March 9, 2021, Stephen P. MacMillan, a director of Boston Scientific since April 2015, advised us that he would not be standing for re-election to the Board at the Annual Meeting. We are deeply grateful for the enormous contributions that Mr. MacMillan has made to our Company, our Board, and our stockholders.

In light of the departure of one director, nine of our directors have been nominated by our Board, upon the recommendation of our Nominating and Governance Committee, to stand for election at the Annual Meeting for a one-year term, to hold office until the 2022 Annual Meeting of Stockholders and until their successors have been elected and qualified. The nominees for election at the Annual Meeting are: Nelda J. Connors, Charles J. Dockendorff, Yoshiaki Fujimori, Donna A. James, Edward J. Ludwig, Michael F. Mahoney, David J. Roux, John E. Sununu and Ellen M. Zane.

Each of the director nominees is willing and able to stand for election at the Annual Meeting, and we know of no reason why any of the nominees would be unable to serve as a director. Should such a situation arise, however, the Board may designate a substitute nominee or, alternatively, reduce the number of directors to be elected. If a substitute nominee is selected, the persons named as proxies will vote for that substitute nominee. Any vacancies not filled at the Annual Meeting may be filled by the Board.

Diverse Range of Experience, Skills and Qualifications Represented by our 2021 Director Nominees

The biography of each of the nominees is listed below and contains information regarding the person's service as a director, business experience, public company director positions currently held or held at any time during the last five years, information regarding involvement in certain legal or administrative proceedings (if applicable), and the experiences, qualifications, attributes or skills that caused the Nominating and Governance Committee and the Board to determine that the person should serve as a director in light of our business and structure. Each of the director nominees listed below exemplifies how our Board values professional experience in business, education, policy and governmental fields as well as strong moral character and diversity in terms of viewpoint as well as age, ethnicity and gender. Our Board believes that these strong backgrounds and sets of skills provide the Board, as a whole, with a strong foundation of technical expertise and a wealth of diverse experience in a wide variety of areas.

Ms. Connors is the founder, chairwoman and chief executive officer of Pine Grove Holdings, LLC, a privately held investment company that acquires and operates small-to-middle market businesses primarily focused in power generation, SAAS, advanced material and transportation/logistics end-markets. She served as president and chief executive officer of Atkore International Inc., formerly the Electrical and Metal Products division of Tyco International, before it became a privately held company in December 2010. Prior to joining Tyco, she served as vice president at Eaton Corporation where she held several positions in operations, continuous improvement, and general management. Prior to joining Eaton, Ms. Connors was employed in a number of executive and management capacities in diversified industrial and automotive end-markets. Her work over 25 years has involved responsibilities in the U.S., Europe, and Asia. Ms. Connors serves as an independent advisor to Nissan North America and previously served as a Class B director of the Federal Reserve Bank of Chicago, and on the boards of Atkore, Blount International, CNH Industrial, N.V., Clarcor, Inc., Echo Global Logistics and Vesuvius plc. She was formerly an appointed member for the Takata Independent Quality Assurance Panel to investigate the airbag inflator recall.

Ms. Connors' qualifications to serve on our Board include her executive leadership skills and her global experience in the areas of operations and financial management, quality, M&A and business strategy, as well as her knowledge of public company matters resulting from her service on other public company boards. She also brings to our Board her experience in National Association of Corporate Directors leadership and governance fellowships.

Mr. Dockendorff was executive vice president and chief financial officer of Covidien plc, a publicly traded medical device and supplies company, and its predecessor, Tyco Healthcare, from 1995 to 2015. Mr. Dockendorff joined the Kendall Healthcare Products Company, the foundation of the Tyco Healthcare business, in 1989 as controller and was named vice president and controller in 1994. He was appointed chief financial officer of Tyco Healthcare in 1995. Prior to joining Kendall/Tyco Healthcare, Mr. Dockendorff was the chief financial officer, vice president of finance and treasurer of Epsco Inc. and Infrared Industries, Inc.

Mr. Dockendorff's qualifications to serve on our Board include his executive leadership experience at public medical device companies, as well as his extensive expertise in accounting, finance and business strategy.

Mr. Fujimori is currently senior executive advisor of Japan to CVC Capital Partners, a position he has held since February 2017. He was an advisor to the LIXIL Group Corporation from June 2016 to December 2019 and was the president and chief executive officer of the LIXIL Group Corporation from August 2011 to June 2016. Prior to joining LIXIL, he was chairman, president and chief executive officer of GE Japan from January 2008 to June 2011. In his 25 years at GE, beginning in October 1986, he held a variety of positions including senior vice president and chief executive officer of a number of Asian and global business divisions, including Medical Systems, Plastics, and Capital. Mr. Fujimori also served as a member of the GE Corporate Executive Council from 2001 to 2010. He formerly served as a director of the Japan Construction Material & Housing Equipment Industries Federation and Tokyo Electric Power Company Holdings.

Mr. Fujimori's qualifications to serve on our Board include his expertise in international business, including developing markets, with a particular emphasis on operations and manufacturing in Japan and Asia, as well as his service on other public company boards.

Ms. James is the founder of Lardon & Associates LLC, a business development and executive advisory services firm, where she has served as president and managing director since April 2006. Ms. James has more than 30 years of diverse management and leadership experience, including her experience at Nationwide Insurance and Financial Services, beginning in 1981. In her 25 years at Nationwide, she served in several leadership roles, including president of Nationwide Strategic Investments, a division of Nationwide Insurance Company, from 2003 to 2006, at which time she had direct responsibility for developing and executing strategies for several U.S. and global financial services subsidiaries and affiliates. Ms. James also is the founder of The Center for Healthy Families, a non-profit in Columbus, Ohio, and the former chair of the National Women's Business Council by presidential appointment. Ms. James currently serves as a director of Xponance (formerly the FIS Group), a privately held asset management and investment advisory firm. She formerly served as a director of Time Warner Cable Inc. and Marathon Petroleum, Inc. and as a board advisor to Marathon Petroleum.

Ms. James's qualifications to serve on our Board include her expertise in business strategy, finance, accounting and human resources. In addition, her service on other public company boards contributes to her knowledge of public company matters.

Mr. Ludwig is the former chairman of the board of Becton, Dickinson and Company (BDX), a global medical technology company, having served in that position from February 2002 through June 2012. He also served as BDX's chief executive officer from January 2000 to September 2011 and as its president from May 1999 to December 2008. Mr. Ludwig joined BDX as a senior financial analyst in 1979. Prior to joining BDX, Mr. Ludwig served as a senior auditor with Coopers and Lybrand (now PricewaterhouseCoopers), where he earned his CPA, and as a financial and strategic analyst at Kidde, Inc. Mr. Ludwig has been a member since 2013 and now Chairman of the Board of POCARED, a privately held company focused on infectious disease diagnostics. He formerly served as a director of Xylem, Inc. and as vice chair of the board of trustees of the Hackensack University Medical Center Network.

Mr. Ludwig's qualifications to serve on our Board include his executive leadership experience, specifically his service as a director and executive of a public medical technology company, along with his extensive expertise in business strategy, finance, management and manufacturing.

Michael F. Mahoney joined the Company as our president in October 2011 and became our president and chief executive officer and a director in November 2012. Mr. Mahoney became our chairman of the Board in May 2016. Prior to joining the Company, he was worldwide chairman of the Medical Devices and Diagnostics division of Johnson & Johnson from January 2011 to September 2011, overseeing 50,000 employees and seven franchises. Prior to assuming this position, Mr. Mahoney served as worldwide group chairman of Johnson & Johnson's DePuy franchise, an orthopedics and neurosciences business, from April 2007 through January 2011. From January 2001 through March 2007, Mr. Mahoney served as president and chief executive officer of Global Healthcare Exchange, a provider of supply chain solutions and services that brings together hospitals, manufacturers, distributors and group purchasing organizations. Mr. Mahoney began his career at General Electric Medical Systems, where he spent 12 years, culminating in the role of general manager of the Healthcare Information Technology business. Mr. Mahoney also serves on the board of the Boys & Girls Club of Boston, is the chair of the board of governors of Boston College CEO Club, and a member of the American Heart Association CEO roundtable.

Mr. Mahoney's qualifications to serve on our Board, in addition to being our Chief Executive Officer, include his management experience leading complex organizations in medical device and other healthcare-related businesses, expertise in building strong leadership teams, developing international markets, and a proven ability to execute successful business strategies and drive operational excellence.

Mr. Roux is co-founder and co-managing partner of BayPine Capital, a private equity partnership established in October 2020. He also is Chairman of Jackson Laboratories, an independent biomedical research institute. He is the co-founder and was the chairman, co-chief executive officer and managing partner of Silver Lake, a private equity firm focused on technology investing, from January 2014 to December 2017. Prior to that, Mr. Roux was chairman and chief executive officer of Liberate Technologies, executive vice president at Oracle Corporation and senior vice president at Lotus Development. He is also chairman of Bristol Seafoods and vice chairman of the National Audubon Society. He previously served as a director of Avaya Inc., Avaya Holdings Corp. and Intelsat S.A. Mr. Roux is co-founder of The Roux Institute, an educational partnership with Northeastern University.

Mr. Roux's qualifications to serve on the Board include his extensive experience in operations, technology, management and business strategy, and his financial expertise and background as an entrepreneur, executive and director.

Senator Sununu served as a U.S. Senator from New Hampshire from 2003 to 2009. He was a member of the Committees on Banking, Commerce, Finance and Foreign Relations, and he was appointed the Congressional Representative to the United Nations General Assembly. Before his election to the Senate, Senator Sununu served three terms as a member of the U.S. House of Representatives from New Hampshire's 1st District from 1996 to 2002, where he was vice chairman of the Budget Committee and a member of the Appropriations Committee. During his twelve years in Congress, he drafted and helped pass several important pieces of legislation, including the Internet Tax Freedom Act, the Survivors Benefit Act and the New England Wilderness Act. Prior to serving in Congress, Senator Sununu served as chief financial officer for Teletrol Systems, a manufacturer of building control systems. Senator Sununu currently serves as a Council Member of Lloyds of London, and formerly served as a director of Time Warner Cable Inc.

Senator Sununu complements our Board with his experience in government and corporate leadership. Senator Sununu provides important insights on government relations, public policy and other matters relevant to our Company due to his extensive experience in both the public and private industry sectors.

Ms. Zane is CEO Emeritus at Tufts Medical Center and Tufts Children's Hospital, and previously, she served as its president and chief executive officer. Ms. Zane also served as Network President for Mass General Brigham (formerly Partners Healthcare System), a physician/hospital network sponsored by the Harvard-affiliated Massachusetts General Hospital and Brigham and Women's Hospital. Ms. Zane also previously served as chief executive officer of Quincy Hospital in Quincy, Massachusetts. Ms. Zane currently is a director of nThrive, a Georgia-based private company involved with healthcare revenue cycle management; Fiduciary Trust Company, a privately owned wealth management company; and AgNovos Healthcare, LLC, a privately held medical device company, focused on bone health. Ms. Zane previously served as a director of Century Capital Management, Parexel International Corporation, Lincare Holdings Inc. and Press Ganey Holdings. Ms. Zane holds a Professional Director Advanced Certification from the American College of Corporate Directors.

Ms. Zane's qualifications to serve on our Board include her executive experience in the healthcare industry, specifically as the chief executive officer of a large urban academic (teaching and research) medical center, in addition to her experience as a director at other public companies.

OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE "FOR" THE ELECTION OF ALL NINE OF THESE NOMINEES FOR DIRECTOR.

To guide the operation and direction of the Board and its committees, our Board has established our Corporate Governance Guidelines, charters for its standing committees and our Code of Conduct to reflect our commitment to good corporate governance and to comply with Delaware law, the rules and listing standards of the NYSE, the rules and regulations of the SEC and other legal requirements. These materials are available under "Governance Overview" in the "Investor Relations" section of our website at www.bostonscientific.com. These materials are also available in print free of charge to stockholders, upon written request to Boston Scientific Corporation, Investor Relations, 300 Boston Scientific Way, Marlborough, Massachusetts 01752.

Our Board believes that good corporate governance is fundamental to the overall success of our business. To that end, our Board evaluates our corporate governance practices in light of applicable changes in Delaware law, the rules and listing standards of the NYSE, the rules and regulations of the SEC, and the rules and regulations under the Internal Revenue Code of 1986, as amended (the Code), as well as best practices suggested by recognized governance authorities, and makes modifications to our corporate governance practices that it determines are warranted.

Under the NYSE's Corporate Governance Standards, a majority of the Board must qualify as independent directors. However, our Corporate Governance Guidelines require that a significant majority of the Board qualify as independent directors. The NYSE Corporate Governance Standards define specific relationships that disqualify directors from being independent and further require that for a director to qualify as independent, the Board must affirmatively determine that the director has no material relationship with our Company (either directly or as a partner, stockholder or officer of an organization that has a relationship with our Company).

In making determinations regarding independence, the Board applies the NYSE standards and broadly considers all relevant facts and circumstances known to it. For directors who will serve on the Compensation Committee, the Board considers all factors specifically relevant to determining whether a director has a relationship with our Company that is material to that director's ability to be independent from management in connection with the duties of a Compensation Committee member, including, but not limited to: (i) the source of compensation of such director, including any consulting, advisory or other compensatory fee paid by our Company to such director, and (ii) whether such director is affiliated with our Company, a subsidiary of our Company or an affiliate of a subsidiary of our Company — as required by the NYSE independence standards for compensation committee members.

The Board has determined that the following directors are independent under the independence standards set forth in the NYSE Corporate Governance Standards: Nelda J. Connors, Charles J. Dockendorff, Yoshiaki Fujimori, Donna A. James, Edward J. Ludwig, Stephen P. MacMillan, David J. Roux, John E. Sununu and Ellen M. Zane.

The Board monitors its compliance with NYSE requirements for director independence on an ongoing basis, including through an annual review of director questionnaires and consideration of transactions and relationships between each director or any member of his or her immediate family and the Company as well as other relevant facts and circumstances. The Board and the Nominating and

Governance Committee considered the directors' responses to a questionnaire asking about their relationships with the Company (and their immediate family members' relationships with the Company) and other potential conflicts of interest, as well as material provided by management related to transactions, relationships or arrangements between the Company and the directors or parties related to the directors. The Board made its determination as to whether any relationship between a director and our Company is a material relationship based on the facts and circumstances of the relationship, the amounts involved in the relationship, the director's interest in such relationship, if any, and such other factors as the Board, in its judgment, deemed appropriate.

The Nominating and Governance Committee is responsible for determining the appropriate skills and characteristics required of new Board members in the context of the current make-up of the Board. In so doing, the Nominating and Governance Committee considers, with input from the Board, those factors it deems appropriate, such as independence, experience, strength of character, judgment, technical skills, diversity, years of experience and the extent to which the individual would fill a present need on the Board. The aim is to assemble a Board that is strong in its collective knowledge and that consists of individuals who bring a variety of complementary attributes and who, taken together, have the appropriate skills and experience to oversee the Company's business. The Nominating and Governance Committee considers diversity as one of a number of factors in identifying nominees for director. The Nominating and Governance Committee views diversity broadly to include diversity of experience, skills and viewpoint, as well as other diversity concepts such as ethnicity and gender. Further, the Board recently adopted an amendment to the Corporate Governance Guidelines that requires that women and racially/ethnically diverse candidates are among the initial slate of candidates presented for consideration in searches for new Board members.

Director nominees must, at a minimum, meet the general criteria outlined in our Corporate Governance Guidelines. Generally, directors should be individuals who have succeeded in their particular field and who demonstrate integrity, reliability, knowledge of corporate affairs and an ability to work well with others, and should also satisfy at least one of the following criteria:

The Nominating and Governance Committee receives suggestions for new directors from a number of sources, including independent Board members and our Chairman and Chief Executive Officer. The Committee may also, at its discretion, employ a third-party search firm to assist in identifying candidates for director.

The Nominating and Governance Committee will also consider recommendations for Board membership submitted by our stockholders and other sources, and considers director nominees for election so submitted if the submission is made in accordance with the advance notice provisions of our By-Laws. The qualifications of candidates recommended by stockholders will be reviewed and considered by the Nominating and Governance Committee with the same degree of care and

consideration as candidates for nomination to the Board submitted by independent Board members and our Chairman and Chief Executive Officer.

Based on engagement with stockholders and benchmarking of corporate governance best practices, the Board amended our By-Laws to add proxy access. Our proxy access By-Law provision permits a stockholder, or group of up to 20 stockholders, meeting certain ownership and other requirements to include a nominee for director election in the Company's Annual Proxy Statement. The Board believes that this change enhances stockholder rights and provides increased accountability of the Company and our Board to our stockholders.

The full Board is responsible for final approval of new director candidates, as well as the nomination of existing directors for re-election. With respect to existing directors, prior to making its recommendation to the full Board, the Nominating and Governance Committee, in consultation with the Chairman of the Board, reviews each director's continuation on the Board as a regular part of the annual nominating process.

Under the advance notice provisions of our By-Laws, director nominations and proposals to bring any other business before the 2022 Annual Meeting of Stockholders by our stockholders must be received by our Corporate Secretary at our principal executive offices on or before November 24, 2021. Under the proxy access by-law provisions of our By-Laws, director nominations submitted for inclusion in our 2022 Annual Proxy Statement must be received no earlier than October 25, 2021 and no later than November 24, 2021. Director nominations by our stockholders must also satisfy the other procedures and requirements set forth in the advance notice and proxy access provisions of our By-Laws, as appropriate. Should you wish to submit a director recommendation or nomination, have it addressed to our Corporate Secretary at Boston Scientific Corporation, 300 Boston Scientific Way, Marlborough, Massachusetts 01752.

The Board has not established any term or age limits to an individual's membership on the Board. While these limits could help ensure that there are fresh ideas and viewpoints available to the Board, they have the disadvantage of causing the Company to lose the contribution of directors who have been able to develop, over a period of time, increasing insight into the Company and its operations and, therefore, provide an increasing contribution to the Board as a whole. The Nominating and Governance Committee, as part of its annual assessment of the composition of the Board, reviews a director's continuation on the Board. The Company believes that, through regular evaluation of

performance and the Company's needs, the Company will continue to achieve the appropriate balance between Boston Scientific experience and fresh ideas and perspectives.

Pursuant to our Corporate Governance Guidelines, the Nominating and Governance Committee reports to the full Board periodically on succession planning for our Chief Executive Officer (and other executive officers, as appropriate). Our Chief Executive Officer discusses with the Board and the Nominating and Governance Committee, at least once per year, his recommendations and evaluations of potential successors to his position, including in the event of an unexpected emergency, and reviews development plans, if any, recommended for such individuals. Additionally, the Nominating and Governance Committee conducts an annual review of the CEO Succession Plan framework, which outlines certain high-level planning, notification and other actions, and is designed to minimize disruption in the event of a temporary or permanent absence of the Chief Executive Officer.

Our Board believes that it is important that it retain flexibility to make the determination as to whether the interests of the Company and our stockholders are best served by having the same individual serve as both Chief Executive Officer and Chairman of the Board or whether the roles should be separated based on the circumstances at any given time. Under our Corporate Governance Guidelines, the Board will appoint a Lead Independent Director when the Chief Executive Officer and Chairman of the Board roles are combined or if the Chairman is not otherwise independent. Pursuant to our Corporate Governance Guidelines, the Lead Independent Director is appointed annually, though is generally expected to serve for a renewable term of three years, subject to annual re-election to the Board. The Lead Independent Director will preside over meetings of our non-management directors, serve as liaison between our Chairman and the independent directors, work with the Chairman to establish agendas for Board and committee meetings, raise issues with management on behalf of the independent directors, consult with committee leadership, and carry out other duties as requested by the Board. The Lead Independent Director also has the authority to call special meetings of independent or non-management directors, as needed.

Mr. Mahoney has been our President and Chief Executive Officer since November 2012 and the Chairman of our Board since May 2016. In light of the fact that the Chief Executive Officer and

Chairman of the Board roles have been combined since May 2016, the Board appointed Mr. Ludwig at that time to serve as Lead Independent Director and re-appointed him to serve in that role for an additional three-year term in February 2019. Mr. Ludwig's qualifications to serve as our Lead Independent Director include his strong leadership experience as Chief Executive Officer and Chairman of the Board of Becton, Dickinson and Company, his service on the Board of CVS Health Corporation and the Chair of that board's Finance Committee, and as lead director on the Board of Aetna, Inc. prior to its acquisition by CVS Health Corporation. Our Board believes that this leadership structure, coupled with a commitment to Board independence, provides effective independent oversight of management, while fostering a constructive and cooperative relationship between the Board and management and allowing both the Board and management to benefit from Mr. Mahoney's day-to-day familiarity with our business operations.

Our Board of Directors conducts annual self-evaluations, overseen by the Nominating and Governance Committee in accordance with the committee's charter. The self-evaluations have been facilitated by a third party and have included in-person and telephonic interviews with directors and presentation of results by the facilitator to our Board and individual directors, as well as written reports to the Board.

Our Board oversees an enterprise-wide approach to risk management, designed to support the achievement of our strategic and organizational objectives, to improve long-term organizational performance and to enhance stockholder value. A fundamental part of risk oversight is to understand the individual risks our Company faces, the steps management is taking to manage those risks, including the framework used by management for the coordinated oversight, control and continuous improvement of processes used to manage risk, and to assess management's appetite for risk. It is management's responsibility to manage risk and bring to the Board's attention material risks facing our Company. Our Board receives regular reports from management on matters relating to strategic and operational initiatives, financial performance and legal developments, which are each integrated with enterprise-risk exposures. The involvement of the full Board in approving our strategic plan is a key part of its assessment of the risks inherent in our corporate strategy.

While the Board has the ultimate responsibility for risk oversight, each committee of the Board also oversees risk to the extent that it relates to the committee's responsibilities, as outlined below. Each committee makes reports in its respective area of responsibility to the Board at the next regularly scheduled Board meeting immediately following the committee meeting.

Given the Board's role in risk oversight, it believes that any leadership structure that it adopts must allow it to effectively oversee the management of the risks relating to our operations. Although there are different leadership structures that could allow our Board to oversee risk management effectively, and while our Board believes our current leadership structure will enable it to manage such risks effectively, it was one factor among many considered by our Board in selecting this leadership structure over other potential alternatives. For a discussion of the reasons why our Board has determined that its leadership structure is appropriate, please see the "Board Leadership Structure" above.

Stockholders and other interested parties who wish to communicate directly with any member of our Board, or our non-management directors as a group, may do so by writing to the Board of Directors or Non-Management Directors, Boston Scientific Corporation, c/o General Counsel, 300 Boston Scientific Way, Marlborough, Massachusetts 01752 or by contacting the Board via email at BSCboardofdirectors@bsci.com or non-management directors at non-managementdirectors@bsci.com. The Board has authorized the office of our General Counsel to review and organize, but not screen, communications from stockholders and other interested parties and deliver them to the Board or non-management directors, as applicable. We do screen commercial solicitations for appropriateness.

The Company is committed to stockholder engagement. In addition to the communication process detailed above, stockholders also have the opportunity to speak at our Annual Meeting of Stockholders, participate in the annual "say-on-pay" advisory vote and communicate with our active Investor Relations department, among other avenues for engagement. The Board seriously considers the views of stockholders in its decision-making process. For example, based on engagement with our stockholders and benchmarking of corporate governance best practices, the Board determined that it was in the best interest of the Company and our stockholders to:

The Board values the input of the stockholders who engaged with us on these important matters, and believes that the changes enhance stockholder rights, provide increased accountability of the Company and our Board to our stockholders, and give us an opportunity to further demonstrate our values and commitment to advancing diversity, equity and inclusion.

Without the approval of the Nominating and Governance Committee, no director may sit on more than four public company boards (including our Board) and our Chief Executive Officer may not sit on more than two public company boards (including our Board). No director may serve simultaneously on the audit committees of more than three public companies (including the Company), unless the Board of Directors has determined that such service would not impair the ability of the member to effectively serve on the Company's Audit Committee, such determination to be disclosed in accordance with applicable NYSE or SEC rules. All of our Board members have complied with these limitations or procedures. In accordance with such procedures, the Nominating and Governance Committee and/or Board, as required, has reviewed and approved the following service of our directors:

Our Board has adopted a written related party transaction policy to monitor transactions, arrangements or relationships in which the Company and any of the following have an interest: (i) any person who is or was (since the beginning of 2020, even if they do not presently serve in that role) an executive officer or director or director nominee; (ii) any person or entity who holds more than a 5% beneficial ownership of our common stock; (iii) any immediate family member of any of the foregoing; or (iv) any entity in which any of the foregoing persons is employed or is a general partner or principal or acts in any similar position in which such person or persons collectively have a 10% or greater beneficial ownership interest. The policy covers any related party transaction that meets the minimum threshold for disclosure under relevant SEC rules (generally, transactions involving amounts exceeding $120,000 in which a related person has a direct or indirect material interest).

Related party transaction oversight is the responsibility of our Nominating and Governance Committee. Our General Counsel is responsible for identifying any potential related party transactions and, if she determines that an existing or proposed transaction constitutes a related party transaction under the policy, she will provide relevant details and an analysis of the related party transaction to the Nominating and Governance Committee. The General Counsel provides an annual summary to the Nominating and Governance Committee of all transactions or relationships which she considered under this policy, including those that she determined do not constitute a related party transaction. If the General Counsel has an interest in a potential related party transaction, she will provide all relevant information to the Chairperson of the Nominating and Governance Committee, who will provide the information to the other members of such Committee. The Nominating and Governance Committee reviews relevant information concerning any existing or proposed transaction contemplated by the Company with an entity that is the subject of a disclosed relationship, and approves or rejects the transaction, with or without conditions or additional protections for the Company. Our related party transactions policy can be found in our Corporate Governance Guidelines available under "Governance Overview" in the "Investor Relations" section of our website at www.bostonscientific.com.

Each of the following related party transactions was ratified by the Company's Nominating and Governance Committee at its February 22, 2021 meeting: As part of our Company's commitment to dismantling systemic racism and promoting equality and diversity, the Company announced that it pledged $1 million over four years to support The New Commonwealth Racial Equity and Social Justice Fund (the "Fund"). Desiree Ralls-Morrison, our Senior Vice President, General Counsel and Corporate Secretary, was a founder and serves in the leadership of the Fund. In 2020, the Company made two donations, totaling $750,000 in the aggregate, to the Fund in support of its pledge.

The son of Joseph M. Fitzgerald, our Executive Vice President, Interventional Cardiology, is employed by the Company as a clinical specialist for our Watchman franchise. During 2020, his total compensation, including base salary and commission, was $144,000. His base compensation was commensurate with that of other employees in similar positions within the Company.

The daughter of Edward F. Mackey, our Executive Vice President, Global Operations, is employed by the Company as a manager, regulatory affairs in our Endoscopy business. During 2020, her total

compensation, including base salary, bonus for 2019 paid in 2020, and taxable income from vesting of a prior year equity award was approximately $167,000. Her compensation was commensurate with that of other employees in similar positions within the Company.

We maintain a Code of Conduct, which has been approved by our Board, to ensure that our directors, employees and officers, including our Chief Executive Officer and Chief Financial Officer, understand the basic principles that govern our corporate conduct. The Code of Conduct is available under "Governance Overview" in the "Investor Relations" section of our website at www.bostonscientific.com. A stockholder may request a copy of the Code of Conduct by contacting our Corporate Secretary at Boston Scientific Corporation, 300 Boston Scientific Way, Marlborough, Massachusetts 01752. Any waivers or substantive amendments of the Code of Conduct will be disclosed on our website at www.bostonscientific.com.

Sustainability is a key focus of our business. We endeavor to reduce our environmental footprint on a global basis, engage with and support the communities where we operate, conduct our operations in a responsible and ethical manner, advance the growth and capabilities or our employees and develop innovative products that improve health care worldwide. By proactively addressing energy consumption, carbon output, waste management, and water use, we are making measurable progress toward shaping a better future for our planet, which directly impacts the wellbeing of our patients, customers, employees, communities, and investors. Using our Global Energy Management System, we implement our C³ strategy — Cut, Convert, Compensate — to cut energy use, convert to renewable sources instead of fossil fuels, and compensate with carbon offset projects as needed. This strategy helps us make progress towards our goals including using 100% renewable electricity by 2024, 90% renewable energy (all sources) by 2027, and achieving carbon neutrality in manufacturing and key distribution sites for all products by 2030.

For more, please see our sustainability report available at www.bostonscientific.com/performancereport.

The Board met eleven times in 2020. In 2020, each incumbent director attended at least 75% of the aggregate of (1) the total number of meetings of our Board of Directors (held during the period for which he or she has been a director) and (2) the total number of meetings of all committees of our Board of Directors on which the director served (during the periods that he or she served).

Directors are expected to prepare for and use reasonable efforts to participate in all Board meetings and meetings of the committees on which they serve. The Board and each committee will meet as frequently as necessary to properly discharge their responsibilities, provided that the full Board will meet at least four times per year. In addition, directors are expected to use reasonable efforts to attend the Annual Meeting of Stockholders. At our 2020 Annual Meeting of Stockholders, all of our directors were in attendance.

Directors who qualify as independent directors within the meaning of the NYSE Corporate Governance Standards meet in executive sessions without management at every regularly scheduled Board meeting and at such other times as they deem appropriate. Our independent directors meet in executive session at least once annually. In 2020, our independent directors met in executive session without non-independent directors six times. The Chairman of the Board, if independent, or the Lead Independent Director, if the Chairman of the Board is not independent, will preside at executive sessions of independent directors. In his absence, the Chair of the Nominating and Governance Committee presides at these executive sessions, and, in his absence, the Chair of the Audit Committee presides.

Our Board currently has standing Audit, Executive Compensation and Human Resources, Nominating and Governance, and Risk Committees. All of the members of the Audit Committee, Executive Compensation and Human Resources Committee, and Nominating and Governance Committee meet the applicable independence requirements of the NYSE and the SEC. Our Board also establishes special committees from time to time to address specific issues or discrete matters as the need arises.

Each of our standing committees is governed by a written charter, which is subject to annual review by each respective committee and approval by the Board. Committee charters are available under "Governance Overview" in the "Investor Relations" section of our website at www.bostonscientific.com.

Our Audit Committee met ten times in 2020. Our Audit Committee is comprised of Messrs. Dockendorff, Roux and Sununu and Ms. Zane, each of whom meets the independence requirements of the NYSE and the SEC. The Board has also determined that each of Messrs. Dockendorff and Sununu and Ms. Zane is an "audit committee financial expert" as that term is defined in the rules and regulations of the SEC.

As outlined in its written charter, the primary purpose of the Audit Committee is to provide oversight of our accounting and financial reporting processes and audits of our financial statements, as well as of our global compliance program, including matters related to compliance with financial, legal and regulatory requirements. The Audit Committee has responsibility to, among other things:

Our Executive Compensation and Human Resources Committee (Compensation Committee) met five times in 2020. Ms. James, Ms. Connors, and Messrs. Ludwig and MacMillan are the current members of the Compensation Committee. The Compensation Committee is, and was during 2020, comprised exclusively of "independent directors," as defined by the NYSE, including under the heightened independence standards applicable to compensation committee members, "non-employee directors" within the meaning of Rule 16b-3 promulgated under the Securities Exchange Act of 1934, as amended (Exchange Act), and "outside directors" within the meaning of Section 162(m) of the Code.

As outlined in its written charter, the Compensation Committee has the responsibility to, among other things:

The Compensation Committee may delegate its authority and duties to subcommittees or individual members of the Compensation Committee, as it deems appropriate in accordance with applicable laws

and regulations. The Compensation Committee has delegated authority to our Chief Executive Officer to make equity grants to new hires and retention awards to existing employees who are not executive officers within predetermined guidelines. These grants are reviewed with the Compensation Committee at its next regularly scheduled meeting. The Compensation Committee may also delegate authority to make amendments to the Company's benefit plans and Global Employee Stock Ownership Plan to the Senior Vice President, Human Resources, that she determines to be necessary to maintain compliance with applicable law or other technical amendments that do not materially increase the cost of the plans to the Company.

Pursuant to its charter, the Compensation Committee has sole authority to retain or obtain advice from any compensation consultant, legal counsel or other advisor, as the Compensation Committee deems appropriate to assist the Committee in the performance of its duties, including the sole authority to approve the compensation and other terms and conditions of retention. Prior to any such retention, and on an annual basis, the Compensation Committee considers any factors relevant to such consultant's, legal counsel's or advisor's independence from management, including the factors specified in the NYSE Corporate Governance Standards or other listing rules, to evaluate whether the services to be performed will raise any conflict of interest or compromise the independence of such consultant, legal counsel or advisor. Semler Brossy Consulting Group, LLC (Semler Brossy) served as the Compensation Committee's independent compensation consultant in 2020. During 2020, Semler Brossy provided the following compensation services to the Compensation Committee:

For additional information regarding the services provided by Semler Brossy, please see the Compensation Discussion & Analysis section.

In 2020, Semler Brossy and its affiliates did not provide additional services to the Company other than at the request of the Compensation Committee. After review and consultation with Semler Brossy, the Compensation Committee determined that Semler Brossy is independent, and there is no conflict of interest resulting from retaining Semler Brossy currently or during 2020. In reaching these conclusions, the Compensation Committee considered the factors set forth in the SEC rules and the NYSE listing standards.

In accordance with its annual review of its compensation consultant engagement, the Compensation Committee will evaluate the engagement of Semler Brossy in May 2021.

The Compensation Committee Report can be found on page 75 of this Proxy Statement.

The Nominating and Governance Committee met four times in 2020. Messrs. Roux and MacMillan, Ms. James, and Ms. Zane are the current members of the Nominating and Governance Committee, each of whom is a non-employee director and meets the independence requirements of the NYSE.

As outlined in its written charter, the Nominating and Governance Committee has responsibility to, among other things:

The Nominating and Governance Committee is also responsible for reviewing with the Board, on an annual basis, the current size, structure and composition of the Board as a whole, and whether the Company is being well served by the current directors taking into account the following: the directors' degree of independence; business background, including any areas of particular expertise, such as accounting or related financial management expertise, marketing or technology; record of service (for incumbent directors), including attendance record; meeting preparation; overall contribution to the Board; employment status; gender; ethnicity; years of experience; availability for service to us; and our anticipated needs.

For information on the nomination process conducted by the Nominating and Governance Committee and our policies regarding stockholder nominations of directors, please see the Corporate Governance section titled "Director Nomination Process."

The Risk Committee met three times in 2020, beginning with its initial meeting in May 2020. Messrs. Sununu, Dockendorff, and Fujimori and Ms. Connors are the current members of the Risk Committee. As outlined in its written charter, the Risk Committee is charged with providing Board oversight of matters relating to (i) the enterprise-wide approach to risk management, (ii) regulatory compliance, (iii) the quality and safety of our products, and (iv) our insurance program.

In March 2020, our Board determined that it would be in the best interests of the Corporation and our stockholders to dissolve the Finance Committee and create a Risk Committee, effective May 6, 2020. Before May, the Finance Committee met one time in 2020.

The members of our Compensation Committee during 2020 were Ms. Connors, Ms. James, Mr. Ludwig and Mr. MacMillan. None of these Compensation Committee members is or has ever been an officer or employee of our Company. During 2020, no member of the Compensation Committee had a relationship that must be described under the SEC rules relating to disclosure of related person transactions. In 2020, none of our executive officers served on the board of directors or compensation committee (or other board committee performing equivalent functions) of any entity that had one or more of its executive officers serving on the Board or the Compensation Committee of the Company.

The Compensation Committee evaluates the appropriate level and form of compensation for non-employee directors at least annually and recommends changes to our Board when appropriate. Non-employee directors receive a combination of cash and equity compensation for their service on our Board. To determine the level of compensation for 2020, the Compensation Committee relied on the consulting services of Semler Brossy, as well as publicly available data describing director compensation in our peer group companies, to establish an appropriate and competitive level of compensation. The Compensation Committee generally aims to provide a level of compensation that is competitive with the median of peer and other similar companies. The Compensation Committee also took into consideration the significant amount of time and dedication required by our directors to fulfill their duties on our Board and Board committees as well as the need to continue to attract highly qualified candidates to serve on our Board. Our director compensation is as follows:

For their service for the annual term beginning on the date of the 2020 annual meeting of stockholders, the non-employee director compensation program is described below and in the following sections:

In April 2020, in light of the disruption and uncertainty created by the evolving COVID-19 pandemic and its anticipated impact on the Company's operations, the Board of Directors determined that, for the one-year term beginning at the 2020 Annual Meeting of Stockholders, for each non-employee director serving on the Board, the annual cash retainer of $115,000 would be temporarily reduced by 50 percent. In the event that a non-employee director elected to receive equity in lieu of the annual cash retainer, as permitted under the Company's non-employee director compensation program, such grant occurred in the ordinary course in connection with the 2020 Annual Meeting of Stockholders but was reduced in value by 50 percent. Additionally, the fee paid to the Lead Independent Director would be reduced by 50 percent, from $40,000 to $20,000.

On September 30, 2020, the Board determined that, due to stronger business results compared with the Company's prior expectations, the annual cash retainer for the Board and the fee for the Lead Independent Director would be restored, beginning with a payment expected to be made during the fourth quarter of 2020. As a result, the aggregate annual cash retainer for the Board and Lead Independent Director fee were two-thirds, rather than one-half, of the previously approved amounts

for the 2020 term. In the event that a non-employee director elected to receive equity in lieu of the annual cash retainer, an additional grant valued at one-sixth of the annual cash retainer was made at or around the time of the payment of the fourth quarter 2020 Board cash retainer.

The annual equity grants are made on the date of each annual meeting of stockholders. If a non-employee director is appointed to the Board on a date other than the annual meeting of stockholders, an equity grant in an amount equal to the then-current non-employee director annual award, prorated for the time period from the effective date of the appointment to the next annual meeting of stockholders, is made on the first trading day of the month following the month in which the new director was appointed to the Board. Such awards made to new non-employee directors become free from restriction upon the expiration of the new director's current term of office on the date of the annual meeting of stockholders immediately following the date of grant, subject to the director's continuation of service during such term. Additionally, if a non-employee director is appointed to the Board on a date other than the annual meeting of stockholders, the annual cash retainer for such director will be prorated for the time period from the effective date of the appointment to the next annual meeting of stockholders.

Each non-employee director receives the annual cash retainer and fees on a quarterly basis. For 2020, each non-employee director could elect to receive all or a portion of his or her cash compensation as one or both of two equity alternatives, each to vest on the date of the annual meeting of stockholders immediately following the date of grant, subject to the director's continuation of service during such term: (i) restricted stock valued based on the closing price of our common stock on the date of grant; and (ii) deferred stock units, valued based on the closing price of our common stock on the date of grant (with shares of our common stock to be issued only after a director's separation from Board service in accordance with the Boston Scientific Non-Employee Director Deferred Compensation Plan, as amended and restated, effective January 1, 2014 (the 2014 Non-Employee Director Deferred Compensation Plan)). Each non-employee director could also choose to defer receipt of all or a portion of his or her annual cash compensation under the 2014 Non-Employee Director Deferred Compensation Plan, as described further below.

The annual equity grants are made on the date of each annual meeting of stockholders and are subject to the terms and conditions of our 2011 Long-Term Incentive Plan (2011 LTIP). In 2020, each non-employee director could elect to receive his or her annual equity award as one or both of the following two equity compensation alternatives, each to vest on the date of the annual meeting of stockholders immediately following the date of grant, subject to the director's continuation of service during such term: (i) restricted stock valued based on the closing price of our common stock on the date of grant; and (ii) deferred stock units valued based on the closing price of our common stock on the date of grant (with shares of our common stock to be issued only after a director's separation from Board service in accordance with the 2014 Non-Employee Director Deferred Compensation Plan).

At the 2020 Annual Meeting of Stockholders, our stockholders voted to approve an amendment and restatement of the 2011 LTIP, which, among other changes, provided that a reasonable annual limit would be imposed on the cash and equity compensation that may be granted or paid to any non-employee director during a calendar year so that the accounting value of equity awards, when

aggregated with cash compensation, granted to a non-employee director in any calendar year does not exceed $600,000.

Directors who are also employees of the Company receive no compensation for serving on the Board or its committees.

We pay or reimburse our directors for transportation, hotel, meals and other incidental expenses incurred in connection with their performance of services for us, including attending Board and committee meetings and participating in director education programs. Our corporate aircraft is made available to our directors for travel to and from our Board meetings, as well as for certain other Company business travel. We also extend directors' and officers' indemnity insurance coverage to each of our directors.

Each non-employee director may, by written election, defer receipt of all or a portion of the annual cash retainer, annual cash committee chair fees and equity compensation under our 2014 Non-Employee Director Deferred Compensation Plan. Cash amounts deferred can be invested in deemed investment options in which we credit the amount deferred plus any earnings from the chosen investment options. Investment options under the plan are generally the same as those offered under the Company's 401(k) Plan through Vanguard, except that, among other things, directors may not elect to invest in the BSC Stock Fund. Deferred cash amounts are payable, at the non-employee director's written election, in either a lump-sum or in annual installments after a director's separation from Board service or in a lump-sum on an earlier fixed date (in all cases, in accordance with the plan).

We believe the stock ownership requirements for our non-employee directors align the interests of our directors with the long-term interests of our stockholders. Our director stock ownership guidelines provide that each non-employee director should own shares with a value equal to at least five times the director annual cash retainer within five years of joining the Board. For purposes of satisfying this obligation, stock units and stock or stock unit deferrals under a Company deferred compensation plan may be included in the aggregate number of shares held by a director. All of our non-employee directors who have served five years or more currently meet our director stock ownership guidelines. The Nominating and Governance Committee monitors compliance with these guidelines on an annual basis. For information regarding the stock ownership guidelines applicable to our Chairman and Chief Executive Officer, please see the Compensation Discussion & Analysis section titled "Executive Stock Ownership Guidelines."

The table below summarizes the compensation paid or earned by our non-employee directors for the year ended December 31, 2020.

Name(1)	Fees Earned or Paid in Cash ($)(2)(3)	Stock Awards ($)(2)(4)(5)	Change in Pension Value and Non-Qualified Deferred Compensation Earnings ($)(6)	All Other Compensation ($)	Total ($)


Nelda J. Connors	76,686	185,000	2,412	–	264,098
Charles J. Dockendorff	101,686	185,000	–	–	286,686
Yoshiaki Fujimori	76,686	185,000	–	–	261,686
Donna A. James	96,686	185,000	–	–	281,686
Edward J. Ludwig	103,360	185,000	–	–	288,360
Stephen P. MacMillan	76,631	185,000	–	–	261,631
David J. Roux	96,686	185,000	–	–	281,686
John E. Sununu	96,686	185,000	–	–	281,686
Ellen M. Zane	76,686	185,000	–	–	261,686


(1)		Mr. Mahoney, the Chairman of our Board, President and Chief Executive Officer, is not included in this table because Mr. Mahoney did not receive any compensation for his services as a director in 2020. His compensation as an executive of the Company is discussed in the Compensation Discussion & Analysis and Executive Compensation sections.
(2)		The "Stock Awards" column and, to the extent a director received equity in lieu of cash compensation, the "Fees Earned or Paid in Cash" column, present grant date fair value (and the notes below present the individual grant date fair values) of each director's equity award computed in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 718. For a description of the assumptions used for purposes of determining grant date fair value, please see Note L — Stock Ownership Plans to our consolidated financial statements included in Item 8 — Financial Statements and Supplementary Data of our Annual Report on Form 10-K for the year ended December 31, 2020.
(3)		Mr. MacMillan elected to receive equity in the form of restricted stock for his entire cash retainer earned in 2020. The following table reports the equity granted to Mr. MacMillan in lieu of cash for the one-year term beginning after the 2020 Annual Meeting of Stockholders. Mr. MacMillan's grants reflect the temporary reduction of the annual cash retainer by fifty percent and subsequent termination of such reduction, as described in the section entitled "2020 Compensation", above.

Name	Equity Award	Grant Date	Number of Shares/ Units(#)	Grant Date Fair Value($)	Vesting Date


Nelda J. Connors	Restricted Stock	May 7, 2020	5,000	185,000	May 6, 2021
Charles J. Dockendorff	Restricted Stock	May 7, 2020	5,000	185,000	May 6, 2021
Yoshiaki Fujimori	Deferred Stock Units	May 7, 2020	5,000	185,000	May 6, 2021
Donna A. James	Deferred Stock Units	May 7, 2020	5,000	185,000	May 6, 2021
Edward J. Ludwig	Deferred Stock Units	May 7, 2020	5,000	185,000	May 6, 2021
Stephen P. MacMillan	Restricted Stock	May 7, 2020	5,000	185,000	May 6, 2021
David J. Roux	Restricted Stock	May 7, 2020	5,000	185,000	May 6, 2021
John E. Sununu	Restricted Stock	May 7, 2020	5,000	185,000	May 6, 2021
Ellen M. Zane	Restricted Stock	May 7, 2020	5,000	185,000	May 6, 2021

Name	Age	Title


Michael F. Mahoney	56	Chairman of the Board, President and Chief Executive Officer
Daniel J. Brennan	55	Executive Vice President and Chief Financial Officer
Arthur C. Butcher	50	Executive Vice President and President, Asia Pacific
Wendy Carruthers	52	Senior Vice President, Human Resources
Jodi Euerle Eddy	48	Senior Vice President and Chief Information and Digital Officer
Joseph M. Fitzgerald	57	Executive Vice President and President, Interventional Cardiology
Edward F. Mackey	58	Executive Vice President, Global Operations
Professor Ian T. Meredith AM	64	Executive Vice President and Global Chief Medical Officer
Jeffrey B. Mirviss	55	Executive Vice President and President, Peripheral Interventions
Maulik Nanavaty	59	Senior Vice President and President, Neuromodulation
Scott Olson	51	Senior Vice President and President,
		Rhythm Management
David A. Pierce	57	Executive Vice President and President, MedSurg and President, Endoscopy
Desiree Ralls-Morrison	54	Senior Vice President, General Counsel and Corporate Secretary
Meghan Scanlon	48	Senior Vice President and President, Urology and Pelvic Health
John Bradley Sorenson	53	Senior Vice President, Manufacturing and Supply Chain
Eric Thépaut	59	Executive Vice President and President, Europe, Middle East and Africa

For Michael F. Mahoney, please see his biography in Proposal 1: Election of Directors.

Daniel J. Brennan is our executive vice president and chief financial officer, a position he has held since January 2014. In this role, he is responsible for several company functions, including global controllership, global internal audit, corporate finance, treasury, corporate tax, investor relations, and corporate business development. Prior to that, he was the Company's senior vice president and corporate controller, a role he served in since January 2010. Since joining Boston Scientific in December 1996, Mr. Brennan has held roles with increased responsibilities, including vice president and assistant corporate controller, vice president of finance and information technology for worldwide financial and strategic planning, investor relations, international finance and Cardiovascular, group controller of the non-vascular business and controller of the Meditech Vascular business. Mr. Brennan is also the Co-Chair of our Global Council for Inclusion. He holds a B.S. degree in Finance and

Investments and an M.B.A from Babson College. Mr. Brennan is also a certified public accountant and a member of the College Advisory Board of Babson College. He currently is a member of the board of directors of Nuance Communications.

Arthur C. Butcher is our executive vice president and president, Asia Pacific, a position he has held since February 2020. In this role, he is responsible for commercialization of our full portfolio of products across all divisions in the Asia Pacific region. Prior to his current role, Mr. Butcher served as our senior vice president and president, Endoscopy, a position he held from July 2016 until February 2020. In this role, he was responsible for developing and bringing to market less invasive devices for treating gastrointestinal and pulmonary conditions. He also served as vice president & general manager, Japan Endoscopy from August 2014 to June 2016. Mr. Butcher has held a variety of marketing and strategic planning management positions within the Endoscopy and Urology and Pelvic Health businesses, including vice president of global marketing, Endoscopy division from April 2011 to August 2014, and vice president of new business development and strategic planning, Urology & Women's Health. Since joining Boston Scientific in 1997, Mr. Butcher has held management roles with increasing responsibility and has deep experience across divisions. Mr. Butcher currently is a member of our Global Council for Inclusion. He holds a B.A. in International Relations from the University of Pennsylvania and an M.B.A. from Columbia University.

Wendy Carruthers is our senior vice president, human resources, a position she has held since December 2012. In this role, she is responsible for overseeing the Company's human resources activities globally, including human resources operations and services, total rewards, talent management, diversity and inclusion and community engagement. Prior to her current role, Ms. Carruthers served as the head of human resources on an interim basis from August 2012 to November 2012, as well as our vice president of global talent management from January 2011 to November 2012. Ms. Carruthers has been with Boston Scientific since 2004 and has held various positions such as, vice president of human resources for our Europe, Middle East and Africa region; vice president of human resources for Europe and director of human resources for Europe. Also, Ms. Carruthers serves as a Co-Chair of our Global Council for Inclusion. Prior to joining Boston Scientific, Ms. Carruthers was vice president of human resources, Europe for Cable & Wireless. Ms. Carruthers holds a B.A. First Class Honors Degree in Modern Languages from the University of Salford and is a Fellow of the Chartered Institute of Personnel and Development. She serves on the Board of Envista Holdings Corporation and the Boston Scientific Foundation and is a member of the Greater Boston Food Bank Emeriti Board.

Jodi Euerle Eddy is our senior vice president and chief information and digital officer, a position she has held since July 2020. In her current role, Ms. Eddy is responsible for positioning the Company for success across multi-disciplinary digital and information technology (IT) needs and overseeing the Company's strategy for digital health, data analytics, and cyber security capabilities. Ms. Eddy leads an IT organization and expanded digital team of employees and contractors worldwide focused on continued advancement into complex, integrated digital solutions to address evolving customer and patient data needs. She served as senior vice president and chief information officer from December 2015 to July 2020. Ms. Eddy joined the Company in December of 2013 as our vice president, Information Systems. She is a member of our Global Council for Inclusion and is the executive sponsor for our HOLA employee resource group, which celebrates Hispanic heritage and provides development and leadership opportunities to its members. Prior to joining Boston Scientific, Ms. Eddy progressed through several roles of increasing leadership of information systems positions over 18 years at General Electric, including serving as the commercial chief information officer for the Oil and Gas business from October 2012 until December 2013; chief commercial information officer for the Measurement and Control business from October 2011 until February 2012; and chief information officer for the Engineered Systems business from October 2008 until February 2011. Ms. Eddy earned

a B.S. in computer science from Southern Connecticut State University. She holds certifications in Master Black Belt Six Sigma, CISSP and CISCO CCNA.

Joseph M. Fitzgerald is our executive vice president and president, Interventional Cardiology, a position he has held since July 2020. In this role, he is responsible for developing and bringing to market innovative solutions that diagnose and treat coronary artery disease and structural heart disorders. He served as executive vice president and president, Rhythm Management, from February 2014 until July 2020, having previously served as senior vice president and president, Cardiac Rhythm Management from July 2011. Prior to that, he was senior vice president and president, Endovascular from February 2010 until July 2011 and president and general manager of Peripheral Interventions and president of Electrophysiology. Mr. Fitzgerald held a variety of management positions in our Neurovascular and Peripheral Interventions businesses. These included numerous regional and divisional sales management assignments up to and including his roles as vice president, global marketing for the Neurovascular business and vice president of U.S. sales for the Neurovascular business. Mr. Fitzgerald is a member of our Global Council for Inclusion. Prior to joining Boston Scientific in 1990 as a sales representative, Mr. Fitzgerald was with Anheuser Busch, Inc., where he held a variety of sales, marketing and training assignments. Mr. Fitzgerald holds a B.S. in Business from Indiana University and an M.B.A. from Southern Illinois University with a concentration in Marketing and Finance.

Edward F. Mackey is our executive vice president, Global Operations, a position he has held since February 2015. In this role, he is responsible for global manufacturing and supply chain, quality and regulatory affairs, IT, global business services, global business excellence, and corporate research and development. Mr. Mackey is a member of our Global Council for Inclusion and is the executive sponsor of our LEAD employee resource group, which promotes the inclusion of individuals with any disability. Prior to joining Boston Scientific, Mr. Mackey was worldwide president of DePuy Synthes Power Tools, a division of Johnson & Johnson from November 2012 to January 2015, and vice president of integration for Johnson & Johnson's acquisition of Synthes from June 2010 to November 2012. Early in his career, Mr. Mackey held management positions in operations, quality and product development at Raytheon's Mille Systems division. In 1995, he moved to Johnson & Johnson Orthopaedics as a plant manager and progressed through a series of manufacturing and supply chain leadership roles, becoming worldwide vice president of supply chain and manufacturing for DePuy. Mr. Mackey holds a Bachelor's degree in Mechanical Engineering from Worcester Polytechnic Institute and an M.B.A from the University of Massachusetts. He is a Board member of the Greater Boston Food Bank.

Professor Ian T. Meredith AM is our executive vice president and global chief medical officer, a position he has held since January 2017. In this role, he is responsible for leading clinical science and medical affairs across Boston Scientific and providing global leadership of the company's clinical trial strategy. Mr. Meredith serves on our Global Council for Inclusion and is an executive sponsor for our PEARL employee resource group, which is a network of employees with an Asian-Pacific focus. Prior to joining Boston Scientific, Professor Meredith served as professor and director of MonashHeart, and executive director of the Monash Cardiovascular Research Centre at Monash University in Melbourne, Australia, from September 2005 to December 2016. Professor Meredith has over 25 years of experience as a clinical and interventional cardiologist and also served as director of the Cardiac Catheterization Laboratories and Interventional Cardiology. Professor Meredith has been a member of the Board of the National Heart Foundation (Australia) and a member of the Cardiac Society of Australia and New Zealand National Board. Professor Meredith received a Ph.D. from the Baker Institute in Melbourne and an Order of Australia (AM) in the General Division for service to medicine in the field of Cardiology as a clinician and researcher. In 2019, Professor Meredith received a Doctor Laws honoris causa from Monash University for distinguished and exceptional service to the field of medicine and healthcare.

Jeffrey B. Mirviss is our executive vice president and president, Peripheral Interventions, a position he has held since February 2020. In this role, he is responsible for developing and bringing to market innovative solutions for treating patients with arterial and venous system blockages and cancer. Prior to his current role, he was our senior vice president and president, Peripheral Interventions, from January 2013 until January 2020, and president, Peripheral Interventions from July 2011 to January 2013. Mr. Mirviss has more than 31 years of experience in medical device and pharmaceutical general management, marketing and sales. Since joining Boston Scientific in 1997, Mr. Mirviss also served as our vice president, Group Global Marketing, Cardiology, Rhythm and Vascular and vice president, Global Cardiology Marketing. Mr. Mirviss is a member of our Global Council for Inclusion and is the executive sponsor of our Women's Network employee resource group. Prior to joining Boston Scientific, Mr. Mirviss worked for companies ranging in size from a pre-revenue venture-backed medical device startup to Dow 30 companies. He holds a Bachelor's degree from the University of Minnesota and an M.B.A. from the University of St. Thomas.

Maulik Nanavaty is our senior vice president and president, Neuromodulation, a position he has held since September 2011. In this role, he is responsible for developing and bringing to market innovative, less-invasive microelectronic implantable technologies used to treat chronic neuropathic pain and neurological diseases such as Parkinson's disease and other chronic conditions. Prior to his current role, Mr. Nanavaty was our president of Boston Scientific Japan; he also served as vice president and general manager, Interventional Cardiology, Boston Scientific Japan. Mr. Nanavaty joined Boston Scientific in 2005 as vice president, corporate strategy, Boston Scientific Japan. Mr. Nanavaty is a member of our Global Council for Inclusion and is the executive sponsor of our SAIL employee resource group, which advances professional development, business growth and corporate citizenship for South Asian employees, patients, physicians and communities. Prior to joining Boston Scientific, Mr. Nanavaty spent 16 years working in various executive positions at Baxter International, Inc. and Baxter Japan. Mr. Nanavaty earned a Ph.D. in Pharmaceutical Sciences from the University of Illinois and an M.B.A. from the University of Chicago.

Scott Olson is our senior vice president and president, Rhythm Management, a position he has held since July 2020. In his current role, Mr. Olson is responsible for developing and bringing to market the most advanced and least invasive rhythm management technologies. Prior to his current role, he served as senior vice president and commercial general manager for our Rhythm Management organization, with responsibility for Rhythm Management global marketing, U.S. sales and commercial operations. Mr. Olson joined Guidant Corporation in 1998, where he held a number of sales positions of increasing responsibility. Following the acquisition of Guidant by Boston Scientific, Mr. Olson held a variety of leadership positions within the Boston Scientific Rhythm Management organization, including vice president of marketing for Cardiology, Rhythm and Vascular and vice president of global marketing of Cardiac Rhythm Management. He has also helped shape our Rhythm Management global commercial organizational model into three franchises: Cardiac Rhythm Management, Electrophysiology, and Cardiac Diagnostics and Monitoring, while leading our portfolio strategy, creating alignment and overall effectiveness to drive success. Also, Mr. Olson is a member of our Global Council for Inclusion. Mr. Olson earned a B.S. and M.B.A from Indiana University, Bloomington.

David A. Pierce is our executive vice president and president, MedSurg a position he has held since April 2018, and president, Endoscopy, a role he has held since February 2020. In this role, he has direct responsibility for the Endoscopy business, corporate marketing and market access, and corporate sales operations, as well as oversight responsibility for the Urology and Pelvic Health business. Prior to his current role, Mr. Pierce served as the Senior Vice President and President, Urology and Pelvic Health since July 2016. In that role, he developed and executed strategies to bring to market industry-leading solutions for treating patients with urological, urogynecological and gynecological diseases. Previously, Mr. Pierce served as senior vice president and president, Endoscopy

since 2011, and vice president, marketing for Endoscopy as well as group marketing director in the Endoscopy business. He joined Boston Scientific in 1991 as a territory manager before assuming management-level positions of increasing responsibility. Mr. Pierce is a member of our Global Council for Inclusion and is the executive sponsor of our VETS employee resource group, which is focused on cultivating gratitude and service to others, particularly active duty veterans and their families. Prior to joining Boston Scientific, Mr. Pierce also served as senior sales representative for Airborne Express and as a Captain in the United States Army. He earned a B.S. in Business Administration from Norwich University and an M.B.A. from Boston University.

Desiree Ralls-Morrison is our senior vice president, general counsel and corporate secretary, a position she has held since November 2017. In this role, she is responsible for providing global legal leadership across all of our businesses, regions and functions, and overseeing the company's global compliance function. Ms. Ralls-Morrison is a member of our Global Council for Inclusion and serves as the executive sponsor for our BRIDGE employee resource group, which focuses on positively influencing the recruitment, development and retention of Black employees, and engaging employees to improve the healthcare of ethnically diverse patient populations. Before joining Boston Scientific, she was senior vice president, general counsel and corporate secretary, and head of the global litigation, government affairs and public policy organizations, for Boehringer Ingelheim USA, Inc. since October 2013. Prior to that, she spent nine years at Johnson & Johnson, most recently as general counsel for the consumer group, and previously progressed through roles of increasing responsibility, including senior counsel, assistant general counsel, and vice president of law for the women's health, nutritionals and over-the-counter businesses. Earlier in her career, Ms. Ralls-Morrison was a senior attorney and assistant counsel at Merck & Co, Inc., focusing largely on regulatory and product liability matters, and prior to that, she held litigation roles at the law firms of Kelley Drye & Warren LLP and Shipman & Goodwin LLP. In September of 2020, Ms. Ralls-Morrison was appointed to the Board of Directors for DICK'S Sporting Goods, Inc. Since October of 2018, she has served on the Board of Directors for The Partnership, Inc., whose mission is to ensure the economic competitiveness of the Boston area by attracting, retaining and convening professionals of color. Ms. Ralls-Morrison is also a Founding Member of The New Commonwealth Racial Equity and Social Justice Fund in Massachusetts. She previously served on the Danbury Hospital/New Milford Hospital Board of Directors, The Inner-City Foundation for Charity and Education and the Lawyer's Collaborative for Diversity. In 2019, Ms. Ralls-Morrison was named one of the most powerful women in corporate America by Black Enterprise Magazine and in 2020, she was named as one on the top innovative General Counsels around the world by the Financial Times. Ms. Ralls-Morrison earned her B.A. in economics and political science from Wesleyan University and her J.D. from Harvard Law School.

Meghan Scanlon is our senior vice president and president, Urology and Pelvic Health, a position she has held since February 2020. In this role, she is responsible for developing and bringing to market innovative, industry-leading solutions for urological, urogynecological, and gynecological diseases. Prior to her current role, Ms. Scanlon served as vice president and general manager for the global Urology and Pelvic Health commercial organization, with responsibility for overseeing the stone, prostate health, prosthetic urology and women's health franchises. She is a member of the Global Council for Inclusion and serves as the executive sponsor for our PRIDE employee resource group, which is a network of LGBTQ+ employees and allies that fosters inclusiveness and professional fulfillment through corporate and community LGBTQ+ programs and initiatives. Since joining Boston Scientific in 2014 as vice president, global marketing for Endoscopy, she has progressed through roles of increasing responsibility in Urology and Pelvic Health and Endoscopy, and played a significant role in driving and shaping the global commercial organization structures and portfolio innovation strategies for both businesses. Prior to joining Boston Scientific, Ms. Scanlon spent nearly 15 years in leadership roles within the Johnson & Johnson medical device business and started her early career as a design

engineer at Gillette. She holds a B.S. in Mechanical Engineering from Tufts University and both her M.B.A. and M.S.M.E. from Massachusetts Institute of Technology.

John Bradley Sorenson is our senior vice president, manufacturing and supply chain, a position he has held since November 2014. In this role, he is responsible for the global manufacturing and distribution of our products. Prior to his current role, he served as multi-site vice president, operations from 2008 to 2014. Mr. Sorenson held a variety of operations positions at Boston Scientific, supporting the Cardiac Rhythm Management, Neuromodulation, Interventional Cardiology, Peripheral Interventions and Structural Heart businesses and has more than 20 years of medical device manufacturing experience. He is a member of our Global Council for Inclusion and serves as the executive sponsor for our Young Professionals Network employee resource group. Before joining Boston Scientific, he was president and chief operating officer of QRS Diagnostic and held manufacturing management positions at Federal Cartridge. Mr. Sorenson earned a B.A. in Economics from Gustavus Adolphus College and an M.B.A. from the University of Minnesota.

Eric Thépaut is our executive vice president and president, Europe, Middle East and Africa, a position he has held since February 2020. Prior to his current role, he was senior vice president and president, Europe, Middle East and Africa from December 2017 to January 2020, and senior vice president and president, Europe from January 2015 to December 2017. He also served as vice president Interventional Cardiology & Structural Heart, Europe, from December 2012 to December 2015. He joined Boston Scientific Europe, in 1996, as a business finance manager and earned roles of increasing responsibility in marketing and finance including vice president, Finance, Europe, general manager and vice president, France, and general manager and vice president of the France Group, comprised of France, Benelux and Middle East North Africa. Mr. Thépaut is a member of our Global Council for Inclusion. Before joining Boston Scientific, Mr. Thépaut held management positions in treasury operations and auditing at Nestlé and financial planning and analysis at Apple, Inc. (then Apple Computer, Inc.). Mr. Thépaut earned his M.B.A. at Paris Dauphine University.

Set forth below are stockholders known by us to be the beneficial owner of more than 5% of our common stock as of March 12, 2021. As of March 12, 2021, there were 1,420,516,801 shares of our common stock outstanding.

(1): Based solely on an amendment to Schedule 13G filed with the SEC on February 5, 2021. As of December 31, 2020, BlackRock reported that it possessed sole voting power with respect to 121,511,492 shares and sole dispositive power with respect to 135,962,117 shares. BlackRock reported that it did not possess shared voting or dispositive power over any shares.
(2): Based solely on an amendment to Schedule 13G filed with the SEC on February 10, 2021. As of December 31, 2020, The Vanguard Group reported that it possessed shared voting power with respect to 2,300,547 shares, sole dispositive power with respect to 104,571,518 shares and shared dispositive power with respect to 6,209,640 shares. Vanguard reported that the following subsidiaries of Vanguard beneficially own shares: (i) Vanguard Asset Management, Limited; (ii) Vanguard Fiduciary Trust Company; (iii) Vanguard Global Advisors, LLC; (iv) Vanguard Group (Ireland) Limited; (v) Vanguard Investments Australia Ltd; (vi) Vanguard Investments Canada Inc.; (vii) Vanguard Investments Hong Kong Limited; and (viii) Vanguard Investments UK, Limited.
(3): Based solely on Schedule 13G jointly filed by Wellington Management Group LLP, Wellington Group Holdings LLP and Wellington Investment Advisors Holdings LLP (known collectively as "Wellington") with the SEC on February 4, 2021. As of December 31, 2020, Wellington reported shared voting power with respect to 71,219,606 shares and shared dispositive power with respect to 77,265,641 shares. Wellington reported that the following subsidiaries of Wellington Management Group LLP, Wellington Group Holdings LLP and/or Wellington Investment Advisors Holdings LLP beneficially own shares: (i) Wellington Investment Advisors LLP; (ii) Wellington Management Global Holdings, Ltd.; (iii) Wellington Management Company LLP; (iv) Wellington Management Canada LLC; (v) Wellington Management Singapore Pte Ltd; (vi) Wellington Management Hong Kong Pte Ltd; (vii) Wellington Management International Ltd; (viii) Wellington Management Japan Pte Ltd; and (ix) Wellington Management Australia Pty Ltd.

The following table shows, as of March 12, 2021, the amount of our common stock beneficially owned by:

"Beneficial ownership" includes those shares of our common stock the reporting person has the power to vote or transfer, stock options that are currently exercisable or exercisable within 60 days, and deferred stock units that may vest within 60 days. Unless otherwise indicated, the persons named below have sole voting and investment power over the shares listed.

Name		Percent of Shares Outstanding


Nelda J. Connors(1)	133,001	*
Charles J. Dockendorff(2)	73,203	*
Yoshiaki Fujimori(3)	23,111	*
Donna A. James(4)	40,363	*
Edward J. Ludwig(5)	85,988	*
Stephen P. MacMillan(6)	88,187	*
David J. Roux(7)	60,005	*
John E. Sununu(8)	117,912	*
Ellen M. Zane(9)	32,043	*
Michael F. Mahoney(10)	5,144,470	*
Daniel J. Brennan(11)	616,281	*
Joseph M. Fitzgerald(12)	1,027,409	*
Edward F. Mackey(13)	331,245	*
Jeffrey B. Mirviss (14)	408,319
All directors and executive officers as a group (25 Persons)(15)	10,100,382	*

*: Reflects beneficial ownership of less than one percent (1%) of our outstanding common stock.
(1): Ms. Connors' beneficial ownership includes (i) 5,000 shares of restricted stock as to which she has sole voting but not investment power as the shares are unvested until the Annual Meeting, (ii) 45,442 shares of common stock held in the Nelda J. Connors Trust, of which she is the sole trustee, and (ii) 54,813 shares of restricted stock and 22,756 deferred stock units, both of which have been deferred pursuant to our Non-Employee Director Deferred Compensation Plan, the underlying shares of which she has neither voting nor investment power until such shares are distributed in accordance with the plan.
(2): Mr. Dockendorff's beneficial ownership includes (i) 5,000 shares of restricted stock as to which he has sole voting but not investment power as the shares are unvested until the Annual Meeting, (ii) 27,299 shares of common stock held in a grantor retained annuity trust, of which he is the trustee and annuitant, and (iii) 40,904 shares of common stock held in the Charles J. Dockendorff Revocable Trust, of which he is the sole trustee.
(3): Mr. Fujimori's beneficial ownership includes 23,111 shares of deferred stock units deferred pursuant to our Non-Employee Director Deferred Compensation Plan, the underlying shares of which he has neither voting nor investment power until such shares are distributed in accordance with the plan.
(4): Ms. James' beneficial ownership includes (i) 21,879 shares of common stock held through The Donna A James Family Trust, of which she is the sole trustee, and (ii) 18,484 shares of deferred stock units deferred pursuant to

our Non-Employee Director Deferred Compensation Plan, the underlying shares of which she has neither voting nor investment power until such shares are distributed in accordance with the plan.

(5): Mr. Ludwig's beneficial ownership includes 32,673 deferred stock units deferred pursuant to our Non-Employee Director Deferred Compensation Plan as to the underlying shares of which he has neither voting nor investment power until such shares are distributed in accordance with the plan, and 16,818 shares of common stock subject to stock options exercisable within 60 days of March 12, 2021.
(6): Mr. MacMillan's beneficial ownership includes (i) 8,000 shares of restricted stock as to which he has sole voting but not investment power as the shares are unvested until the Annual Meeting, (ii) 45,694 deferred stock units deferred pursuant to our Non-Employee Director Deferred Compensation Plan the underlying shares of which he has neither voting nor investment power until such shares are distributed in accordance with the plan, and (iii) 34,493 shares of common stock subject to stock options exercisable within 60 days of March 12, 2021.
(7): Mr. Roux's beneficial ownership includes 5,000 shares of restricted stock as to which he has sole voting but not investment power as the shares are unvested until the Annual Meeting.
(8): Mr. Sununu's beneficial ownership includes (i) 5,000 shares of restricted stock as to which he has sole voting but not investment power as the shares are unvested until the Annual Meeting and (ii) 21,708 shares of restricted stock and (iii) 60,049 deferred stock units, both of which have been deferred pursuant to our Non-Employee Director Deferred Compensation Plan, the underlying shares of which he has neither voting nor investment power until such shares are distributed in accordance with the plan.
(9): Ms. Zane's beneficial ownership includes 5,000 shares of restricted stock as to which she has sole voting but not investment power as the shares are unvested until the Annual Meeting.
(10): Mr. Mahoney's beneficial ownership includes 3,027,683 shares of common stock subject to stock options exercisable within 60 days of March 12, 2021.
(11): Mr. Brennan's beneficial ownership includes 353,038 shares of common stock subject to stock options exercisable within 60 days of March 12, 2021.
(12): Mr. Fitzgerald's beneficial ownership includes (i) 702,286 shares of common stock subject to stock options exercisable within 60 days of March 12, 2021, (ii) 68,305 shares held in his 401(k) Plan account and (iii) 6,038 shares of common stock held by his children, as to which Mr. Fitzgerald disclaims beneficial ownership.
(13): Mr. Mackey's beneficial ownership includes 239,350 shares of common stock subject to stock options exercisable within 60 days of March 12, 2021.
(14): Mr. Mirviss's beneficial ownership includes 269,161 shares of common stock subject to stock options exerciseable within 60 days of March 12, 2021.
(15): This amount includes 5,802,008 shares of common stock subject to stock options exercisable within 60 days of March 12, 2021 and 70,859 shares held in the 401(k) Plan accounts of our executive officers. Please refer to footnotes 1 through 14 above for additional details regarding the holdings of our directors, our director nominees and our Named Executive Officers.

Section 16(a) of the Exchange Act requires our directors, executive officers and persons beneficially holding more than 10% of our common stock to file with the SEC reports of their ownership of our common stock and any changes in that ownership. To our knowledge, all of these filing requirements were timely satisfied in 2020. In making this statement, we have relied upon the written representations of our directors and executive officers and copies of reports that have been filed with the SEC.

This discussion and analysis section describes material elements of our 2020 compensation program for our Named Executive Officers (NEOs), which include our Chief Executive Officer (CEO), our Chief Financial Officer (CFO), and our three other most highly-compensated executive officers. NEOs for the year ended December 31, 2020 were as follows:

During 2020, our management team responded to the challenges presented by the COVID-19 pandemic with swift and decisive actions. First and foremost, we focused on keeping our employees safe, while continuing to support our patients and customers. We effectively managed liquidity and debt, took the decisive action required early in the pandemic to avoid laying off our employees and to be prepared for a strong recovery, and continued to work toward many of our strategic goals, including those relating to product pipeline and digital enablement, as well as key ESG, human capital, and innovation metrics. Ultimately, we believe our response to the challenges of 2020 will enable us to continue to focus on the following five strategic imperatives to help drive innovation, improve the health of patients across the globe, accelerate profitable revenue growth, and increase stockholder value in 2021 and beyond:

We believe that continued focus on these strategic imperatives will benefit patients and customers and lead to strong performance across key financial metrics, including those incorporated into our short-and long-term incentive programs, described in further detail below.

Our short- and long-term incentive plans incorporate metrics designed to align with the objective of driving profitable growth and reward Company and individual progress related to the strategic imperatives. Below is a snapshot of 2020 adjusted financial performance metrics used in our short- and long-term incentive programs, as well as the most directly comparable reported metrics:


(1)		Adjusted net sales, adjusted EPS and adjusted free cash flow are not prepared in accordance with generally accepted accounting principles in the United States (GAAP). For a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures and insight into how these non-GAAP measures are considered by management, please see Annex A.
(2)		Adjusted net sales excludes the impact of foreign currency fluctuations. Adjusted EPS excludes the impact of goodwill and intangible asset impairments, acquisition- and divestiture-related net charges, restructuring and restructuring-related net charges, litigation-related net charges, investment impairment charges, EU Medical Device Regulation implementation costs, deferred tax expenses (benefits), discrete tax items, and amortization expense.
(3)		3-year Total Shareholder Return for the period from January 1, 2018 to December 31, 2020. Please see the Executive Compensation section titled "2020 Total Shareholder Return Performance Share Program" for how we calculate Total Shareholder Return.

Our executive compensation philosophy is to provide appropriate competitive compensation opportunities to our executives with actual pay outcomes tied to achievement of Company and individual performance targets in support of our business strategy and creation of long-term stockholder value.

Each year, the Compensation Committee assesses our CEO's actual compensation relative to the Company's performance. The following graph shows the relationship of our CEO's total direct compensation (as disclosed in the Summary Compensation Table) (TDC) compared against our cumulative total shareholder return (TSR) performance in each of the last three years. The TDC in this

chart consists of base salary and annual short- and long-term incentives. As illustrated, CEO compensation was generally aligned with Company performance.

CEO Compensation(1)
Summary Compensation Table Total Direct Compensation
versus 3-Year Total Shareholder Return(2)


(1)		Amounts in the 2018, 2019, and 2020 columns were calculated as follows:
		• the values of the annual equity awards granted on February 15, 2018, February 21, 2019, and February 18, 2020 were determined in accordance with FASB ASC Topic 718, as described in the footnotes to the Executive Compensation section titled "Summary Compensation Table";
		• the actual Annual Bonus Plan award for 2018, 2019, and 2020; and
		• the annual base salary earned in 2018, 2019, and 2020.
(2)		Total shareholder return was calculated in accordance with the methodology described in the Executive Compensation section titled "2020 Total Shareholder Return Performance Share Program" and based on $100 invested on December 31, 2017.

The following chart shows the value of the primary elements of total direct compensation, consisting of base salary and annual short- and long- term incentives, for our CEO in 2020 (i) at "target" opportunity as considered by our Compensation Committee; (ii) as disclosed in our Summary Compensation Table; and (iii) as "realizable" at December 31, 2020. These values were calculated using the 2020 base salary, annual equity incentives and Annual Bonus Plan ("ABP") award amounts for our CEO as set forth in the table following the chart below.

	Valuation of Compensation Component

	Base Salary	ABP Award	Long-Term Incentives

Target	Annual base salary approved in February 2020	Target 2020 Annual Bonus Plan award	Annual equity awards granted on February 18, 2020, with (a) stock options valued in accordance with FASB ASC Topic 718 and (b) service-based deferred stock units (DSUs) and performance-based DSUs valued at target (the number of units and target units awarded multiplied by the closing price of our common stock on the date of grant).
Summary Compensation Table	Annual base salary earned in 2020	Actual 2020 Annual Bonus Plan award	Annual equity awards granted on February 18, 2020, with the value of each award determined in accordance with FASB ASC Topic 718.
Realizable	Annual base salary earned in 2020	Actual 2020 Annual Bonus Plan award	Annual equity awards granted on February 18, 2020, with: (a) stock options valued at their intrinsic value (number of options awarded multiplied by the closing price of our common stock on December 31, 2020 less the exercise price of such options); (b) service-based DSUs valued using the number of units awarded multiplied by the closing price of our common stock on December 31, 2020; (c) Total Shareholder Return (TSR) performance-based DSUs valued using 0% of the target TSR performance-based DSUs due to the Company's TSR rank being 57^th out of 57, or 0^th percentile (0% of the target number of units multiplied by the closing price of our common stock on December 31, 2020); and (d) the free cash flow (FCF) performance-based DSUs valued using 88.6% of the target FCF performance-based DSUs (the actual percentage of target units earned under the program) multiplied by the closing price of our common stock on December 31, 2020.

The difference in value of the long-term incentive compensation portion of our CEO's TDC reflected in the "Realizable", "Target", and "Summary Compensation Table" columns is primarily due to three factors:

This demonstrates the sensitivity of CEO pay to the achievement of performance criteria, and, therefore, the linkage between our executive compensation program and the long-term interests of our stockholders. The long-term incentive portion of the CEO's compensation will remain "at-risk" and the value will vary until the completion of the vesting periods or until the exercise date for each of the equity awards.

A Significant Portion of our NEOs' 2020 Target TDC is At-Risk, Performance-Based Compensation

Our Compensation Committee ties a significant portion of our executives' target TDC to at-risk, performance-based incentive opportunities. For 2020, approximately 90.8% of the target value of the primary elements of TDC for our CEO and approximately 80.3% of the target value of the primary elements of TDC for our other NEOs as a group consisted of at-risk, performance-based incentive compensation, comprised of short-term incentives (Annual Bonus Plan award) and long-term incentives (performance- and service-based equity awards and stock options). For more details and a breakdown of the elements of TDC, please see the section titled "Elements of 2020 Executive Compensation, Primary Elements of Total Direct Compensation".

The percentages above were calculated using the 2020 base salary, target equity values and target Annual Bonus Plan award amounts for our NEOs. The allocation of the target value of the primary elements of TDC for our CEO and for our other NEOs as a group in 2020 was as follows:

We believe our emphasis on at-risk, performance-based incentive compensation aligns our executives' financial interests with our business strategy and the short- and long-term interests of our stockholders, providing "pay for performance" and putting a significant portion of our executives' pay "at risk."

Our Compensation Committee believes that a strong foundation for our compensation program is necessary to execute our executive compensation philosophy effectively. The following best practices serve as the foundation for our executive compensation program:

At our 2020 Annual Meeting of Stockholders, we asked our stockholders to approve, on an advisory basis, the 2019 compensation of our then-NEOs as disclosed in our 2020 Proxy Statement, commonly referred to as a "say-on-pay" advisory vote. Our stockholders approved the compensation of our then-NEOs with approximately 94.5% of the votes cast voting in favor of the proposal. In connection with its review of our compensation program against our executive compensation philosophy, business objectives and peer group practices, our Compensation Committee considered the prior years' modifications to our compensation programs in support of our executive compensation philosophy and best practices, the results of the say-on-pay advisory vote, as well as prior stockholder feedback. As a result, our Compensation Committee concluded that it would retain the overall structure and design of our compensation program, including its emphasis on at-risk, performance-based incentive compensation.

Our philosophy is to provide appropriate competitive compensation opportunities to our executives such that actual pay outcomes are heavily influenced by achievement of Company, business and individual performance targets and objectives, which are designed to support our business strategy and create long-term stockholder value. The core objectives of our compensation program are to:

Our Compensation Committee bears principal responsibility for, among other things, structuring our executive compensation program and making individual executive compensation determinations. To help facilitate informed determinations with respect to its responsibilities, our Compensation Committee engages an independent compensation consultant, Semler Brossy Consulting Group, LLC (Semler Brossy), which serves at the direction and under the supervision of our Compensation Committee. For further information about our Compensation Committee and the services provided by Semler Brossy, please see the Meetings and Board Committees section titled "Executive Compensation and Human Resources Committee." Semler Brossy and certain members of management support our Compensation Committee with respect to the following, among other things:


Independent Advisor
*Semler Brossy* Advisor to the Compensation Committee		• Expertise-based advice, research and analytical services, including peer group composition, trends and comparative practices in executive compensation, program design and non-employee director compensation. • Commentary and/or recommendations as to the foregoing. • Participation in Compensation Committee meetings.
Management
*Senior Vice President, Human Resources,* and *Total Rewards Management Team*		• Proposals, including regarding compensation and benefits design and pay levels, for executives' employment arrangements for new or promoted executives. • Reporting and advisory on diversity and inclusion topics, including pay equity. • Expertise-based advice, research and analytical services, commentary and/or recommendations as to the foregoing. • Participation in Compensation Committee meetings.
*Chief Executive Officer and other Executives*		• Overview of individual performance of direct reports. • Recommendations as to compensation of direct reports. • With respect to the CEO and General Counsel, participation in Compensation Committee meetings, except for determinations of their own compensation.

Our Compensation Committee uses competitive market analysis as a decision-making reference. The Committee primarily considers executive compensation comparative data for our peer group companies to better understand trends and comparative practices, program design in the market within which we compete for top talent, and competitive levels and mix of target compensation opportunities provided to our executives. Our peer group includes companies (i) operating in a comparable industry with respect to customer base and/or product offerings, such as healthcare equipment and services companies, pharmaceuticals, and biotechnology and life sciences, and (ii) that, in the aggregate, approximate our size as measured by revenue and market capitalization.

Each year, with the assistance of its independent compensation consultant, our Compensation Committee reviews the composition and appropriateness of our peer group. The Committee considers the size, performance, and business focus of these companies in comparison to us. The peer companies used to establish 2020 compensation levels include:

			Total Shareholder Return (%)(2)

	Revenue ($ in billions)	Market Cap ($ in billions)	Total Shareholder Return (%)(2)
	Revenue ($ in billions)	Market Cap ($ in billions)	One Year	Three Year

Abbott Laboratories	$34.6	$193.9	29.95%	102.97%
Agilent Technologies, Inc.(3)	$5.5	$36.7	41.66%	70.75%
Baxter International Inc.	$11.7	$40.5	–2.53%	25.79%
Becton, Dickinson and Company	$18.2	$72.7	–5.62%	13.09%
Danaher Corporation	$22.3	$157.8	56.42%	144.29%
Edwards Lifesciences Corporation	$4.4	$57.0	6.03%	128.10%
Hologic, Inc	$4.0	$18.8	42.72%	73.92%
Intuitive Surgical, Inc.	$4.4	$96.3	31.19%	98.18%
Medtronic plc (4)	$27.9	$150.0	2.73%	46.48%
Quest Diagnostics Incorporated	$9.4	$15.9	19.18%	34.95%
Stryker Corporation	$14.4	$92.1	14.58%	54.03%
Thermo Fisher Scientific, Inc.	$32.2	$184.6	51.21%	148.19%
Zimmer Biomet Holdings, Inc.	$7.0	$32.0	1.64%	31.20%
Boston Scientific Corporation	$9.9	$50.9	–19.02%	30.90%
Ranking Relative to Peers	8 of 14	9 of 14	14 of 14	12 of 14

In establishing 2020 pay levels for our NEOs, the Compensation Committee reviewed comparative pay information for the peer group companies through proxy research and survey data as reported in the Equilar, Radford, and Willis Towers Watson surveys. Where peer group information was unavailable, the Committee reviewed industry-specific survey data which was calibrated to include companies

comparable to our size and scope of each individual's responsibilities. The Company considers market data without regard for any particular percentile positioning. This allows us to retain flexibility to make individual decisions that reflect both market and internal considerations, including those described below under "Internal Pay Equity and Other Considerations."

In addition to the competitive market analysis, the Committee considers multiple factors in formulating compensation decisions. These factors include:

In considering internal pay equity, and the elements of an executive officer's TDC opportunity compared to the other executive officers, the Committee also considers CEO compensation relative to the other executive officers. The Committee strives to maintain the appropriate balance in order to motivate the Company's executive team, retain key personnel in a highly competitive labor market, and support a robust succession planning process. The differences between CEO and NEO pay reflect the foregoing factors, as well as the Company's organizational structure.

We utilize a performance, development and coaching (PDC) process to help guide individual development and performance discussions and to assess ongoing performance. Our CEO undertakes regular PDC reviews for all direct reports, assesses the performance results of those direct reports and makes recommendations to our Compensation Committee for its consideration. Our Compensation Committee reviews and evaluates our CEO's performance objectives and oversees the evaluation of his performance in relation to those objectives. For 2020, the overall performance of our executives, including our NEOs, supported a culture of high performance, integrity and accountability with clear expectations. These performance evaluations, among the other considerations described in this section, influence the Compensation Committee's decisions regarding our executives' base salaries, the individual component of their Annual Bonus Plan awards and, as an indication of future performance potential, their long-term equity incentive awards.

The application of CEO and Compensation Committee judgment is an important factor in setting and determining executive pay. We do not employ a purely formulaic approach to our executive compensation program. Target market guidelines and individual target TDC, financial and operational targets, individual performance objectives and funding formulae are established in advance; however, other Company and individual performance and other considerations may also be taken into account. For example, under the 2020 Annual Bonus Plan, while the funding formula tied to Company-level

financial performance targets are set in advance, our Compensation Committee is able to reduce the total Annual Bonus Plan funding percentage (Total Bonus Pool), to not less than 50% of the target, based on (i) its assessment of the Company's progress toward achievement of our quality objectives, which are critical to our commitment to providing high quality products to our customers and patients, or (ii) based on performance against operating income margin targets, which takes into consideration the Company's profitability and commitment to our shareholders, as well as affordability of the proposed bonus funding.

Further, in March 2020, due to the uncertainty around the potential impacts of the COVID-19 pandemic, the Compensation Committee resolved to permit the exercise of discretion in the determination of the 2020 Annual Bonus Plan funding percentage. The Committee anticipated that potentially using discretion at the end of the year to set funding was more prudent than approving multiple revisions of the performance targets, in light of the evolving pandemic. A description of the exercise of discretion in determining the Annual Bonus Plan funding this year is set forth in the section titled "Total Bonus Pool Funded Based on Company Performance."

We compensate our executives primarily through total direct compensation, namely in the form of base salary and short- and long-term incentives (the primary elements of TDC). Our primary elements of TDC are heavily weighted towards variable, at-risk performance-based elements, which are reflected below and in the charts under the section above titled "A Significant Portion of our NEOs' 2020 Target TDC is At-Risk, Performance-Based Compensation." These percentages were calculated using the 2020 base salary, target equity values and target Annual Bonus Plan award amounts for our NEOs set forth in the footnotes to the charts under the section titled "A Significant Portion of our NEOs' 2020 Target TDC is At-Risk, Performance-Based Compensation."

The key features and objectives of the primary elements of our NEOs' 2020 TDC are summarized in the table below.

TDC Elements	Key Features	Objectives


Base Salary	Fixed annual cash amount, paid at regular intervals.	Attract and retain talented executives and provide stable source of income.
Short-Term Incentives — Annual Bonus Plan Awards	At risk, performance-based annual cash incentive opportunity.	Align executive compensation with our business strategy, quality, and profitability objectives.
	—Funding of Total Bonus Pool based on Company performance against two important financial performance targets.	Focus and reward based on the achievement of important financial, operational and individual performance objectives.
	—Allocation of funded Total Bonus Pool, based on regional, business and functional performance against specific financial and/or operational performance targets.
	—Actual payout based on individual performance.
Long-Term Incentives — Equity Awards	At risk, performance-based equity incentive opportunity.	Focus talent/organization on important financial measures and long-term stockholder value.
	Mix of opportunity comprised of:	Reward based on:
	—25% target TSR performance-based DSUs	—our TSR relative to that of other S&P 500 Healthcare Index companies
	—25% target FCF performance-based DSUs	—our adjusted free cash flow measured against our target performance
	—25% stock options	—our stock price increase
	—25% service-based DSUs	—our stock price

In determining the 2020 base salaries of our NEOs (other than our Chief Executive Officer), our Compensation Committee also considered the recommendations of our Chief Executive Officer in light of the general factors discussed above, including their overall performance ratings for the prior year.

The 2020 base salaries (rounded to the nearest thousand) for our NEOs, as well as the percentage increase from their 2019 base salaries for our current NEOs who were also NEOs in 2019, are set forth below.

In April 2020, the Company announced that, in light of the disruption and uncertainty created by the evolving COVID-19 pandemic and its anticipated impact on the Company's operations, all of our Executive Officers, including our NEOs, would take a significant temporary reduction in base salary for up to six months. During this time, Mr. Mahoney took a 99% reduction in his salary and our other NEOs each took a 40% to 50% reduction in their salaries. In August 2020, the Company announced that the base salary reductions for the Company's Executive Officers, other than the Chief Executive Officer, would terminate and revert to previously approved levels. Mr. Mahoney's salary reduction continued until the end of the six-month period, ending in October 2020. For additional disclosure regarding the salaries earned by our NEOs, please see the footnotes to the Executive Compensation section titled "Summary Compensation Table".

Our Compensation Committee annually reviews the design of our Annual Bonus Plan to help ensure that the program continues to support our executive compensation philosophy and core compensation program objectives. In finalizing the design for 2020, our Compensation Committee retained substantially all of the provisions of our 2019 Annual Bonus Plan, which was designed to reinforce the concept of "pay for performance," align our short-term incentives with important financial and operational measures and the long-term interests of our stockholders, and to incentivize and reward individual performance. The Compensation Committee also retained the discretion to reduce the Total Bonus Pool funding percentage, regardless of financial achievements, to 50% of the target, based on its assessment of the Company's achievement of our quality objectives, and based on performance against the operating income margin target. This discretion reinforces our commitment to providing quality products for our customers and patients and takes into consideration the Company's profitability and value creation for our shareholders, as well as affordability of the proposed bonus funding.

Further, in March 2020, due to the uncertainty around the potential impacts of the COVID-19 pandemic, the Compensation Committee resolved to consider the exercise of discretion in its determination of the funding for the 2020 Annual Bonus Plan. In February 2021, after a fulsome review of Company performance, the Committee decided to use discretion in determining 2020 Annual Bonus Plan funding, as is described further below in the section titled "Total Bonus Pool Funded Based on Company Performance."

The 2021 Annual Bonus Plan, which was approved by the Compensation Committee in November 2020, retained many of the same provisions of our 2020 Annual Bonus Plan, however, the Compensation Committee added a human capital scorecard, which will allow management and the Committee to consider progress toward diversity, equity, and inclusion (DE&I), engagement and retention, and ESG goals in addition to retaining important financial and quality/operational measures in making total bonus pool funding decisions. Adding this human capital scorecard underscores the Company's commitment to these goals and will incentivize Company-wide progress in these areas. Further, the 2021 Annual Bonus Plan removes the operating income margin target as a modifier and eliminates the 50% floor for funding.

After funding the Total Bonus Pool, the actual amount of an executive's Annual Bonus Plan award is ultimately determined as follows:

In prior years and, as contemplated under the 2020 Annual Bonus Plan, a single Company-wide Total Bonus Pool is funded by the Company's performance measured against important Company-level financial and operational performance metric targets, thereby reinforcing the importance of the Company's performance as a whole (which reflects the performance of our regions, businesses and functions).

In approving the 2020 Annual Bonus Plan, the Compensation Committee selected Adjusted EPS and Adjusted Net Sales as our Company-level financial metrics and, in March 2020, the Committee approved performance targets as follows:

At that time, our Compensation Committee also approved the Total Bonus Pool funding scale for the Company's 2020 performance measured against our 2020 Company-level performance metric targets

for adjusted EPS and adjusted net sales set forth in the table below. Each metric was expected to have a 50% weighting.

The Committee's approval of these Company-level Annual Bonus Plan performance targets and funding scales was based on an annual operating plan developed with much uncertainty about the potential impacts of the COVID-19 pandemic on our business. For this reason, as part of its approval process in March 2020, the Committee acknowledged the potential need to exercise discretion in determining bonus funding, as permitted under the 2020 Annual Bonus Plan, to account for the possible and unknown severity of the pandemic's impact on our business in 2020.

The COVID-19 pandemic did have a significant impact on our business in 2020. The significant deferral of and lowered demand for elective procedures, combined with COVID-related disruption to our operations, resulted in a substantial decrease in revenues and adjusted earnings per share. As a result, both our net sales and EPS performance were below threshold levels under the Plan, which would have yielded a 50% funding factor for the Total Bonus Pool Funding.

After approving the possible use of discretion in determining the funding level for the 2020 Annual Bonus Plan, the Committee regularly discussed and assessed, with input from Semler Brossy, its compensation consultant, COVID-19's impact on the business and on the possible bonus plan funding for 2020.

In the second quarter, the effects of COVID-19 began to materially impact our results. The uncertainty and instability caused by COVID-19 made it extremely difficult to predict, throughout 2020, what the total impact of the pandemic would be on our business in 2020. Given this ongoing uncertainty, the Committee determined that it was not appropriate to revise our 2020 Company-level financial performance metric targets. Instead, the Committee, with support from Semler Brossy, developed a scorecard that would help assess management's performance in addressing the business disruption COVID-19 caused in 2020. The scorecard included the following categories of key performance indicators: Financial Performance, Strategic Initiatives, COVID Response, Actions Towards Future Success, and Employee Actions.

Holistic Evaluation of Performance and Achievement and Exercise of Positive Discretion

After undertaking a holistic evaluation of Company performance in light of the critical actions and strategic achievements listed in the table below, the Committee used positive discretion to adjust the 2020 Annual Bonus Plan funding from 50%, the level that would've been indicated based on the plan approved prior to COVID-19, to 77%, as described more fully below.



		Financial Performance

		• Developed alternative financial models in early April, based on early estimates of COVID-19 impact and measured 2020 performance against those models • Optimized cash inflows and outflows, including capital expenditures and inventory • Increased Company liquidity from $1.8B in March to $4.5B in June • Successfully negotiated of banking facility to increase permitted debt to earnings ratio • Completed $1.7B bond offering at historically low rates for our credit rating tier • Completed $2.0B equity offering to reduce debt; provide funds for tuck-in M&A • Reduced debt maturities to only $250M through Q2 2022 • Significantly reduced operating expenses

		Strategic Initiatives, COVID Response, and Actions Towards Future Success


		• Prioritized employee safety, patient needs and business continuity in a pandemic
		• Quickly put in place business continuity taskforce to address pandemic-related challenges, as well as a Clinician Emergency Response Team (CERT) to ensure employee illness protocols and effective contact tracing were in place. Travel restrictions, work from home requirements, and preventative measures at sites were rapidly introduced.
		• Developed Key Capabilities to improve agility of remote working and accelerate digital capabilities to remove barriers to growth, innovate and differentiate
		• Community Support
		• Contributed over $18 million in aid to global COVID-19 relief efforts, through monetary and supply donations and by providing engineering and manufacturing expertise and resources. We also doubled down on our commitment to diversity, equity, and inclusion and took actions both internally and externally to confront racism and advance social justice
		• Human Capital Metrics
		• Conducted approximately 7,500 open discussion sessions with employees and presented multiple programs related to social and racial justice.
		• Grew diverse talent pipeline in support of our diversity representation goals (known as 3UP 2023 Goals) that are published on our website (https://www.bostonscientific.com/en-US/careers/working-here/diversity-and-inclusion.html).
		• Progressed on journey to Carbon Neutrality
		• Made considerable progress in the following four areas: Renewable Energy, Green Real Estate, Energy Management, Carbon Neutrality 2030, which resulted in an improvement in our Sustainability Rankings
		• Progressed against innovation and new product launch metrics



		Employee Actions


		• Took decisive action early in the pandemic to avoid unnecessary layoffs with temporary reductions in pay, including more significant reductions for Executive Officers and Board of Directors, totaling $2.2 million, plant scale backs, hiring freeze, and global employee stock ownership plan pause for second half of year
		• Took ongoing actions throughout the year to protect the safety and well-being of BSC's employees, including travel restrictions, self-quarantines and work-from-home measures
		• Supported over 36,000 employees worldwide by enhancing online wellbeing site and through multiple enhancements to benefit programs to meet employee needs.

Key among the Committee's considerations was Company performance against the approved financial plan, which would have resulted in funding the 2020 Annual Bonus at the 50% funding floor. The Committee also reviewed Company performance against two alternative financial models, both presented in early April, which were based on early estimates of the potential impact of COVID-19 on our business. The first alternative financial model would have resulted in a bonus funding between 70% and 82.5% and the second would have suggested a bonus funding at over 100%.

The Committee's decision to exercise positive discretion in approving the 2020 Total Bonus Pool reflects the Committee's collective judgment in balancing the final, actual results against the approved plan with where the results could have ended in an extremely challenging business environment, had it not been for the critical role employees and the executive team played in navigating the Company through the performance year and preparing the Company for 2021 and beyond. The Committee reviewed Company performance against the original bonus plan targets, the revised financial models, our original Quality Goals and Objectives, and the key strategic accomplishments listed above, and considered the Company's strong response to the COVID-19 pandemic. After doing so, in accordance with the terms of the plan, our Chief Executive Officer recommended, and our Compensation Committee approved a Total Annual Bonus Pool Funding of 77%, for approximately 15,000 eligible employees including our NEOs.

In prior years, the Total Bonus Pool, as funded, is allocated by the Compensation Committee to each participating regional, business, and functional unit taking into consideration our Chief Executive Officer's recommendations in light of that participating unit's performance measured against its operational and/or financial performance metric targets (and other factors the Compensation Committee deems appropriate), thereby incentivizing and rewarding each participating unit's performance contributions. However, in order to balance the uneven impact of the COVID-19 pandemic on our global businesses, regions, and functions, the Compensation Committee, upon the

recommendation of our CEO, determined that all participating units would have a Participating Unit Performance Percentage of 75% under the 2020 Annual Bonus Plan.

Each executive's target award opportunity under the Annual Bonus Plan is expressed as a percentage of his or her annual base salary and is determined based on the scope of the executive's responsibilities. For 2020, our Compensation Committee maintained the target award opportunities for our 2019 NEOs in 2020. The following table shows target award opportunities in 2020 for our NEOs, and, for those NEOs who were also NEOs for 2019, their target opportunities in 2019. The target award opportunities for Messrs. Brennan, Fitzgerald, Mackey, and Mirviss were based on the recommendations of our CEO, internal pay equity relative to our other executives, their impact and experience in their roles and external market data.

After year end, individual performance is considered pursuant to the PDC process described in the "Performance Considerations" section above. Based on the performance assessment rating under our annual PDC process, an individual performance multiplier from 0% to 150% is applied to an executive's funded Annual Bonus Plan award to determine the actual amount to be paid. Final payout for each executive may therefore range from 0% to 225% of target, as the product of the funded award under Participating Unit performance percentage, ranging from 50% to 150% of target, and the individual performance multiplier, ranging from 0% to 150%.

Our NEOs had certain performance objectives intended to support our strategic imperatives, as applicable to their roles, including (i) with respect to our NEOs who support corporate functions, those aimed at driving Company-level financial performance objectives, and (ii) with respect to Messrs. Fitzgerald and Mirviss who each supports a business or businesses, those aimed at supporting business-level financial and operational performance objectives. The individual performance objectives discussed below represent factors that are considered by the Compensation Committee and our CEO in determining each NEO's individual performance percentage. Further, no single factor is determinative or required to be considered.

Named Executive Officer		Individual Performance


Michael F. Mahoney	Objectives:	— Driving regional, business, and functional performance — Strengthening category leadership, expanding into high-growth adjacencies, and diversifying portfolio — Driving global expansion — Driving profitability to fuel growth — Developing our people capabilities and our leadership pipeline
	Assessment:	Notable accomplishments include leading the Company to preserve earnings and optimize cash flow, in anticipation of the pandemic's impact to the Company's business, supporting employees globally, by implementing programs to maximize employee safety and well-being, making decisions to strengthen our balance sheet, executing significant product launches, to better position the Company for a strong recovery as the impacts from the pandemic decrease. Mr. Mahoney ensured key leadership moves as well as the advancement of digital capabilities to support customers. He made significant progress towards environmental sustainability goals and strengthened commitment to social justice.
Daniel J. Brennan	Objectives:	— Driving functional performance — Maintaining best-in-class control environment — Achieving financial goals and implementing cost-savings initiatives — Overseeing business development initiatives and supporting strategic transactions — Strengthening relationships with investors and analysts
	Assessment:	Notable accomplishments include implementing an impactful liquidity strategy to enable financial flexibility, acting swiftly to cut costs, and creating a strategic cash management office to closely monitor key company metrics and raise action plans, all to help the Company weather the global pandemic. Mr. Brennan continued his focus on ensuring a best-in-class control environment and maintained the Company's strong relationships with investors, analysts, and ratings agencies. He also drove improvements in diversity, equity, and inclusion culture for global finance organization and the Company as a whole.

Named Executive Officer		Individual Performance


Joseph M. Fitzgerald	Objectives:	— Driving business performance for Rhythm Management, while he led that organization, for Corporate Accounts and then for Interventional Cardiology in his new role — Achieving key product milestones — Effectively executing product launches — Enhancing organizational capabilities
	Assessment:	Notable accomplishments include achieving key regulatory, clinical, and commercial milestones in both Rhythm Management and Interventional Cardiology, making tough, but necessary, decisions to restructure the business, and providing overall leadership of Corporate Accounts. Mr. Fitzgerald also drove digital innovation, made key talent moves, and continued to build a diverse leadership pipeline.
Edward F. Mackey	Objectives:	— Continually improving and sustaining strong quality culture — Delivering key regulatory milestones — Driving optimization of manufacturing and supply chain, global business services, and information technology to support sustainable, profitable growth — Managing acquisition integrations to drive synergies — Enhancing organizational capabilities
	Assessment:	Notable accomplishments include leading the business continuity planning and execution in the face of the global pandemic, including developing and implementing safety and business continuity plans for all company facilities, and scaling existing technology to handle massively increased remote work volumes. Mr. Mackey also continued to execute on key product launches, lead strategic initiatives to deliver productivity and cost savings, and drive the development of our digital strategy. He also continued to drive programs focused on diversity, equity, and inclusion within organization.

Named Executive Officer		Individual Performance


Jeffrey B. Mirviss	Objectives:	— Driving business performance for Peripheral Interventions — Achieving key product milestones and executing product launches — Leading continued integration of BTG plc — Enhancing organizational capabilities
	Assessment:	Notable accomplishments include achieving key regulatory, clinical, and commercial milestones, continuing the successful integration of BTG plc to retain talent, achieve revenue goals, and drive synergies, implementing necessary spending cuts to weather the global pandemic, and continuing to drive engagement within Peripheral Interventions and build a diverse leadership pipeline. Mr. Mirviss also provided effective oversight of our Latin America, Canada, and Government Affairs teams.

Short-term Incentive Awards Paid to Our NEOs Under Our 2020 Annual Bonus Plan

Our Compensation Committee annually reviews the design of our Long-Term Incentive Program (LTI Program) to help ensure that the program continues to support our executive compensation philosophy and core compensation program objectives. In setting the design for 2020, our Compensation Committee retained the mix of equity award opportunities for our executives under our prior LTI Program that were designed to further reinforce "pay for performance" and align the interests of our executives and their compensation with important Company financial measures and the long-term interests of our stockholders. The key features and objectives of each equity vehicle are summarized in the table below.



		Performance-Based DSUs (50% of total mix) 50% Relative TSR; 50% Adjusted Free Cash Flow

		Performance-based DSUs are intended to complement the performance orientation of our other equity vehicles — which are linked to the appreciation of our share price — and further align the interests of our shareholders and executives. This linkage is achieved by tying vesting opportunities to the attainment of goals that are leading indicators of our financial health and ability to create substantial value for our shareholders. At this time, the Compensation Committee believes that adjusted free cash flow and relative TSR are the best measures of long-term success, as they promote strong capital discipline, prioritize sustainable value creation, and align the interests of our executives and shareholders.

		*Relative TSR DSUs(1)(2)* Relative TSR performance-based DSUs align the interests of our executives and shareholders by measuring our total value creation against the S&P 500 Healthcare Index, which includes the majority of our peer companies, and encourages our executives to think like owners and make long-term oriented decisions. Performance is measured across three years, and shares vest between 0% and 200% of target based upon actual achievement. For 2020 TSR DSUs, the performance schedule was as follows: • Participants earn 40% of the relative TSR DSUs if our performance is at the 30^th percentile of the index (our payout threshold value). • All shares are forfeited for performance below the 30^th percentile, and a maximum of 200% of shares are earned for achievement at or above the 80^th percentile. • Payouts are linearly interpolated between points on the payout grid. • Awards typically vest upon satisfaction of both performance and service criteria at the end of the three-year performance period.



		*Free Cash Flow DSUs(1)(2)(3)* FCF performance-based DSUs, in conjunction with the measures in our annual incentive plan, align executive compensation opportunities with achievement of a key objective in the Company's internal financial plan and an important area of focus for stockholders. The performance period of one year maximizes our nimbleness in a highly variable operating environment, while the three-year service criteria (inclusive of the performance period) promotes a long-term orientation and retention. In 2020, our Adjusted Free Cash Flow target goal was $2.100 billion, which aligned with the Board-approved 2020 internal cash flow plan. • Participants earn 25% of the FCF DSUs if our performance is at 50% of plan. • All shares are forfeited for performance below 50% of plan, and a maximum of 150% of shares are earned for achievement at or above 125% of plan. • Payouts are linearly interpolated on the payout grid. • Any shares earned vest in full three years following the grant date.

		*Service-Vesting Equity Vehicles (50% of total mix)(1)(2)*** 50% Service-Based DSUs; 50% Non-Qualified Stock Options

		*Service-Based DSUs*
		Service-based DSUs reinforce pay for performance by linking the ultimate value of the award to performance of our stock. The vesting period acts as a retention tool and promotes executive long-term share owner perspective.

		• For awards granted in 2020, DSUs vest in four equal annual installments subject to continued service
		• Service-based DSUs granted under programs prior to 2019 vested in five equal annual installments
		• Promote executive ownership and linkage to our share price

		*Non-Qualified Stock Options(1)*
		Non-qualified stock options represent the right to purchase our common stock at an exercise price equal to the closing price of our common stock on the date of grant. As such, executives only receive value to the extent that our share price increases through the exercise period.

		• Vest in four equal annual installments subject to continued service
		• Provide value only to the extent that our share price increases
		• Are exercisable from the vesting date through the tenth anniversary of the grant date

For further discussion of the performance share programs for our Company performance-based DSUs and the equity awards granted pursuant to our Long-Term Incentive Plans (LTIPs) and a description of how we calculate adjusted free cash flow, please see the Executive Compensation sections titled "Narrative Disclosure to Summary Compensation Table and Grants of Plan-Based Awards Table — 2020 Total Shareholder Return Performance Share Program," "Narrative Disclosure to Summary Compensation Table and Grants of Plan-Based Awards Table — 2020 Free Cash Flow Performance Share Program" and "Narrative Disclosure to Summary Compensation Table and Grants of Plan-Based Awards Table — Amended and Restated 2011 Long-Term Incentive Plan" and Annex A.

In February 2020, our Compensation Committee approved the grant of long-term equity incentive awards to our NEOs in the amounts in the following table, which were based on the target dollar values of the long-term equity incentive awards for our NEOs considered by the Compensation Committee (see discussion of the target dollar values below). In approving the following grants, the Committee considered external market data and internal factors, including internal equity, performance, and potential. In evaluating internal equity between the CEO and non-NEOs, the Committee focused, in particular, on competitive market data, and the Company's organizational structure.

The numbers of FCF and TSR performance-based DSUs and service-based DSUs were calculated by dividing the target dollar value of those awards by the closing price of our common stock on the date

of grant, and the numbers of stock options were determined by dividing the target dollar value of that award by the stock option value determined in accordance with FASB ASC Topic 718, as described in the footnotes to the Executive Compensation section titled "Summary Compensation Table".

We also made equity grants to two of our NEOs outside of the ordinary annual award process. In February 2020, Mr. Mackey was awarded 23,719 DSUs for retention purposes, which vest in a single installment on February 18, 2022, the second anniversary of the grant. Additionally, in July 2020, in connection with Mr. Fitzgerald's appointment to the position of Executive Vice President and President, Interventional Cardiology, Mr. Fitzgerald was granted an equity incentive award in the form of 116,959 non-qualified stock options, which have an exercise price of $35.28 per share and vest in one single installment on January 1, 2023. The grant date fair value of each of these equity grants was approximately $1,000,000.

Company Performance-Based DSUs — Results for Performance Periods Ended December 31, 2020

In February 2021, our Compensation Committee determined the number of deferred stock units earned pursuant to our performance-based DSUs under the 2018 TSR Performance Share Program and the 2020 FCF Performance Share Program, presented in the table below.

We also compensate our executives, including our NEOs, with indirect compensation, namely in the form of benefits and limited perquisites. Generally, our benefits and perquisites are targeted to be competitive relative to our peer group companies. The primary elements of and objectives for our NEOs' 2020 indirect compensation are summarized below.

We provide employee benefits to eligible employees, including our NEOs, to promote personal health and well-being and to provide certain financial security and protection upon retirement or in the event of death, disability or illness. As U.S.-based employees, our NEOs are eligible to receive employee

benefits under our U.S. employee benefits program, which consists of the following key elements that are generally the same as those provided to our other U.S. salaried employees:

In addition, our executive officers may participate in an annual executive level physical examination program that is designed to encourage the proactive management of executive health. In approving the program, the Compensation Committee considered the overall cost of the program (estimated to be less than $10,000 per participant) and the importance of good health to an executive's ability to focus on the short and long-term needs of the Company. Company-paid term life insurance premium amounts (and related imputed income), Company matches of 401(k) Plan contributions for our NEOs, Company-paid executive level annual physical examination costs, and certain other reimbursements in 2020 are reported in the footnotes to the Executive Compensation section titled "Summary Compensation Table."

We maintain a Deferred Bonus Plan for certain of our management, including our NEOs, in order to provide them with the opportunity to defer up to 75% of their annual award under our Annual Bonus Plan until the earlier of termination of employment or an elected distribution date. However, in April 2020, the Compensation Committee determined that no deferral elections would be permitted under the Deferred Bonus Plan for the 2020 Annual Bonus, if any, payable in 2021. For additional discussion of the Deferred Bonus Plan, please see the narrative to the Executive Compensation section titled "Nonqualified Deferred Compensation."

We provide tiered relocation benefits under our relocation program to eligible employees, including our NEOs, whom we request to move in connection with their current position or a promotion and for eligible new hires we require to move in connection with accepting a position with us. Our objectives in providing relocation benefits are to attract and redeploy top talent. We provide "tax gross-ups" on applicable relocation benefits provided under our relocation program as we believe that this benefit is integral to the Company's ability to attract and retain employees whose skill or knowledge enhance the Company's competitive position. Participants are generally required to sign a reimbursement agreement that requires them to pay back expenses incurred by the Company for their relocation in the event that they voluntarily terminate their employment or are terminated for "cause" at a rate of 100% for termination within one year of the date on which payments were first made and 50% for termination following the first year but within two years of the date on which payments were first made.

Pursuant to Mr. Mahoney's offer letter, he is permitted reasonable personal use of our corporate aircraft up to $100,000 per year in aggregate incremental cost to the Company. Our other executives are permitted limited personal use of our corporate aircraft with prior approval. These executives are personally taxed on their personal use of our corporate aircraft and we do not provide them with income tax gross-up payments. The aggregate incremental cost to the Company (and disallowed tax deductions of the Company) for our NEOs' personal use of our corporate aircraft in 2020 is included in the footnotes to the Executive Compensation section titled "Summary Compensation Table."

We offer a financial planning perquisite for our executive officers, including our NEOs. The program provides financial counseling and planning, investment and retirement management, insurance planning, and income tax planning and preparation services through a single service provider for US-based executive officers. Executive officers located outside of the United States will be eligible for reimbursement. In approving the program, the Compensation Committee considered the overall cost of the benefit (up to $12,000 per participant), prevalence of the benefit in the market, and benefit to the Company of reducing potential distraction to executive officers of complex personal financial situations.

None of our NEOs has an employment agreement with the Company. However, we provide post-employment and change in control payments and benefits to our executives under certain circumstances. We believe that offering our executives these payments and benefits facilitates the operation of our business, allows them to better focus their time, attention and capabilities on our business, and assists the Company in recruiting and retaining key executives. The primary elements of and objectives for our NEOs' 2020 post-employment and change in control agreements are summarized below.

Our executives are eligible to participate in our defined benefit Executive Retirement Plan. For further discussion of our defined benefit Executive Retirement Plan, please see the narrative to the Executive Compensation section titled "Defined Benefit Retirement Plan."

We maintain severance plans for eligible employees, including our NEOs, under which participants are entitled to receive certain severance payments, subsidized COBRA health benefits and dental benefits for specified periods of time. For further discussion of our severance plans, please see the Executive Compensation section titled "Potential Payments Upon Termination or Change in Control — Severance Plans."

We have entered into change in control agreements to our executives, including our NEOs, and other key employees (Change in Control Agreements). The possibility of a change in control and the

uncertainty that it may raise among our executives as to their continued employment after or in connection with a change in control may result in their departure or distraction. Our objective in providing Change in Control Agreements is to retain and encourage the continued attention and dedication of our executives during a potentially critical time, even if they are concerned that their position will be eliminated after or in connection with the change in control. Our Change in Control Agreements require both a change in control and termination without cause or resignation for good reason within two years after the change in control event, commonly referred to as a "double-trigger," for cash payments to be made under the agreement and vesting to be accelerated under the agreements for equity awards where the surviving or acquiring entity substitutes or assumes outstanding equity awards.

For further discussion of our Change in Control Agreements, other plans and arrangements under which a change in control and/or termination of employment triggers payments or benefits, and potential payments to our NEOs under the foregoing, please see the narrative and tables in the Executive Compensation section titled "Potential Payments Upon Termination or Change in Control — Change in Control Agreements."

Our Compensation Committee has adopted a policy regarding the recovery or adjustment of short-term incentive awards paid to an executive in the event relevant Company performance measures are restated in a manner that would have reduced the size of a previously granted award. In such an event, and to the extent permitted by applicable law, the Company would seek to recover the amount of the short-term incentive award paid to such executive that was in excess of the amount that would have been awarded based on the restated financial results, subject to and in accordance with the terms of the policy. Our Compensation Committee monitors regulatory developments with respect to applicable executive compensation recovery policies required by the Dodd-Frank Wall Street Reform and Consumer Protection Act and it expects to consider such changes to the Company's current recovery policy as are necessary to comply with final rules (and related guidance, if any) to be issued by the SEC in accordance with such act.

Our Compensation Committee has also adopted a policy regarding the recovery of certain short- and long-term incentive compensation awards paid or granted to an executive in the event of executive misconduct or gross dereliction of duty that resulted in a material violation of Company policy and caused significant harm to the Company. In such an event, and to the extent permitted by applicable law, the Company may seek reimbursement of all or a portion of cash incentive compensation awards paid within a certain time period and/or recovery of all or a portion of equity incentive awards granted to such executive over which the Company retains control, subject to and in accordance with the terms of the policy.

Both of the policies described above are only applicable to awards made after the adoption of the relevant policy. For a discussion of other recovery and forfeiture provisions relating to incentive compensation awards and other benefits provided to our executives, please see the section titled "Relocation Program" above, and the Executive Compensation sections titled "Retirement Plan Benefits" and "Narrative Disclosure to Summary Compensation Table and Grants of Plan-Based Awards Table."

Our executives are required to have a significant personal investment in the Company through their ownership of shares of our common stock. Our Board has set stock ownership guidelines for

executives, including our NEOs, as a number of shares of Company stock equal in value to at least the following amounts:

Executives are required to comply with the guidelines at all times. However, if at any time an executive's ownership does not meet or exceed the guideline, he or she is expected to retain ownership of at least fifty percent of net shares with respect to each vesting of an equity award or stock option exercise until the guideline is met or exceeded. For purposes of satisfying the guidelines, shares owned outright, shares held in company benefit plans and the intrinsic value of vested "in-the-money" stock options are included in the aggregate number of shares held by an executive. Unvested equity award shares (including service-based DSUs and performance-based DSUs) and unvested stock options are not included in the aggregate number of shares held by an executive. The Nominating and Governance Committee monitors compliance with these guidelines on an annual basis. As of December 31, 2020, our CEO and other NEOs were in compliance with these guidelines.

The Company does not provide tax gross-ups for our executives, except for relocation benefits because the benefit generally applies to all employees eligible to receive relocation benefits, including our executives, and the Compensation Committee believes it is integral to the Company's ability to attract and redeploy employees whose skill or knowledge enhance the Company's competitive position.

Under our Equity Award Grant Policy, grants of equity awards to our executives are approved and effective as follows:

Section 162(m) of the Code (Section 162(m)), as amended by the Tax Cuts and Jobs Act, generally disallows a tax deduction to public companies for compensation over $1 million paid to certain "covered employees," which includes a company's CEO, CFO, and the three other most highly compensated executive officers employed by the company at the end of the year. Once an officer is a

"covered employee," their compensation will remain subject to Section 162(m) for so long as they are receiving compensation from the company. Further, the Tax Cuts and Jobs Act repealed the exclusion for "qualified performance-based compensation" under Section 162(m) effective January 1, 2018, except for compensation payable pursuant to a written binding contract in place before November 2, 2017 that is not materially modified thereafter (a grandfathered arrangement). The company may avail itself of this transition rule for grandfathered arrangements, to the extent applicable and that our existing plans and outstanding awards qualify. To maintain flexibility in compensating executive officers in a manner designed to promote varying corporate goals in the best interest of the Company, the Committee does not limit its actions with respect to executive compensation to preserve deductibility under Section 162(m) if the Committee determines that doing so is in the best interests of the Company.

The Company accounts for stock-based compensation in accordance with FASB ASC Topic 718, which requires the Company to recognize compensation expense for share-based payments (including stock options and other forms of equity compensation). FASB ASC Topic 718 is taken into account by the Compensation Committee in determining to use a portfolio approach to equity grants, awarding both stock options and DSUs.

Our executives, including our NEOs, and our directors, are prohibited from speculating in the Company's securities, engaging in transactions designed to "hedge" the value of our common stock, and pledging their common stock as collateral for a loan. Examples of hedging and pledging transactions specifically covered by the policy include zero-cost collars and forward sale contracts, and use of stock as margin to secure borrowings, respectively. To facilitate the implementation of this prohibition, excluded from the policy's general prohibition on hedging and pledging arrangements are shares held by directors that were subject to hedging or pledging arrangements as of December 31, 2010, and do not in the aggregate for all directors amount to more than 3.5% of the Company's then outstanding shares. None of our executives or directors is engaged in hedging or pledging arrangements related to the Company's securities.

With the assistance of the senior members of our Global Compensation and Benefits organization, certain senior executive officers and the Compensation Committee's independent compensation consultant, Semler Brossy, in February 2021 the Compensation Committee reviewed a risk assessment of our compensation programs and policies to determine if the provisions and operations of our programs create undesired or unintentional risk of a material nature.

Our risk assessment included two work streams — one focused on reviewing areas of enterprise risk and the other focused on identifying compensation design risk. Our enterprise risk analysis examined the types and magnitudes of risks our business areas present to the Company so that the Committee could assess the extent to which our compensation programs may mitigate or exacerbate these risks. Our compensation design risk analysis, which was conducted by management and reviewed by Semler Brossy, examined the potential risks in the design of our performance-based incentive compensation arrangements. As part of this assessment, we analyzed the mix of fixed and variable compensation; the mix of short- and long-term compensation; the mix of long-term equity incentives; performance metric mix; weighting, measurement and payout timing; discretion and caps on short-term incentives; award size, vesting schedules and performance and other terms of long-term equity incentives; and other incentive opportunities and their features. We also analyzed our recovery of incentive awards policy, executive stock ownership guidelines and hedging and pledging prohibitions. Finally, we evaluated on a combined basis the results of the enterprise and compensation risk assessments, on a business area-by-business area basis.

The Compensation Committee reviewed and discussed the findings of this analysis with management and concluded that it continues to believe that our compensation programs do not create risks that are reasonably likely to have a material adverse effect on the Company.

The Compensation Committee has reviewed and discussed the Compensation Discussion & Analysis contained in this Proxy Statement with management and, based on such review and discussions, the Compensation Committee has approved the inclusion of the Compensation Discussion & Analysis in this Proxy Statement and in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020 for filing with the SEC.

This Compensation Committee Report does not constitute soliciting material and should not be deemed filed or incorporated by reference into any other Boston Scientific filing with the SEC, except to the extent that Boston Scientific specifically incorporates this Report by reference into another Boston Scientific filing.

The table below summarizes the total compensation for each of our named executive officers for the years ended December 31, 2020, 2019 and 2018. For a narrative description of material factors helpful to understand the information disclosed in the table below for 2020, please see the Compensation Discussion & Analysis and the narrative to this table.

Name and Principal Position	Year	Salary ($)(1)	Stock Awards ($)(2)	Option Awards ($)(3)	Non-Equity Incentive Plan Compensation ($)(4)	Change in Pension Value and Nonqualified Deferred Compensation Earnings ($)(5)	All Other Compensation ($)(6)	Total ($)


Michael F. Mahoney	2020	666,878	8,395,367	2,749,991	1,485,000	399,686	76,873	13,773,795
Chairman of the Board, President	2019	1,274,740	9,087,249	2,699,992	1,996,800	409,290	296,069	15,764,140
and Chief Executive Officer	2018	1,234,630	7,643,884	2,499,993	2,128,770	311,932	151,692	13,970,901
Daniel J. Brennan	2020	560,422	1,907,997	624,992	455,206	99,172	21,204	3,668,993
Executive Vice President and	2019	655,437	1,977,244	587,497	583,482	190,385	37,241	4,031,286
Chief Financial Officer	2018	621,637	1,719,882	562,495	626,736	102,017	33,058	3,665,825
Joseph M. Fitzgerald	2020	568,679	1,907,997	1,624,991	414,010	59,902	22,754	4,598,333
Executive Vice President and	2019	667,416	2,103,497	624,989	546,760	60,063	22,732	4,025,457
President, Interventional Cardiology	2018	639,958	1,910,971	624,994	582,425	245,334	32,636	4,036,318
Edward F. Mackey(7)	2020	497,670	2,144,740	374,991	391,374	170,059	20,692	3,599,526
Executive Vice President, Operations	2019	577,398	1,472,367	437,491	520,282	156,573	34,851	3,198,962
Jeffrey B. Mirviss(7)	2020	495,001	1,450,047	474,996	350,179	155,410	30,563	2,956,196
Executive Vice President and President, Peripheral Interventions


(1)		Base salaries for our executive officers are generally effective for one year starting in late February of each year. The amounts in this column for 2018 and 2019 reflect an amount calculated by prorating the prior year's base salary until late February, and then 2018 and 2019 base salaries, respectively, for the remainder of the year. In April 2020, the Company announced that, in light of the disruption and uncertainty created by the evolving COVID-19 pandemic and its anticipated impact on the Company's operations, all of our Executive Officers, including our NEOs, would take a significant temporary reduction in base salary for up to six months. For our NEOs other than Mr. Mahoney, the temporary salary reductions were terminated in August 2020, and for Mr. Mahoney, the reduction ended in October 2020. Therefore, for each NEO, the amounts in this column for 2020 reflect an amount calculated by prorating the individual's 2019 salary from January 1, 2020 through February 16, 2020; then prorating the regular 2020 base salary and temporarily reduced base salary amounts for the applicable periods throughout the year.
		For each year, these figures differ from those in the Compensation Discussion & Analysis, which lists amounts approved by the Compensation Committee for 2020.
(2)		The amounts included in the "Stock Awards" column represent the aggregate grant date fair value of all service-based and Company performance-based DSUs granted in 2020, 2019 and 2018 under our 2011 LTIP, as effective on the respective dates of grant. These values have been determined in accordance with FASB ASC Topic 718.
		The attainment of the performance-based DSUs awarded to our NEOs in 2020 is based on either (i) the Total Shareholder Return (TSR) of our common stock relative to the TSR of the common stock of the other companies in the S&P 500 Healthcare Index over a three-year performance and service period, or (ii) our adjusted free cash flow over a one-year performance period measured against our 2020 internal financial plan for the same period, subject to the satisfaction of the service criteria over a three-year period (inclusive of the performance period). For additional information with respect to these Company performance-based DSUs, including the vesting thereof, please see the sections titled "2020 Total Shareholder Return Performance Share Program" and "2020 Free Cash Flow Performance Share Program" in the narrative to this table.


		The TSR performance metric for the 2020 TSR performance-based DSUs is a market condition as defined under FASB ASC Topic 718. Because these awards do not have performance conditions as defined under FASB ASC Topic 718, such awards have no maximum grant date fair values that differ from the fair values presented in this Summary Compensation Table.
		The grant date fair value of the 2020 FCF performance-based DSUs was determined based on management's evaluation of the Company's 2020 internal financial plan for adjusted free cash flow, assuming target achievement of the adjusted free cash flow performance criteria and utilizing the closing price of our common stock on the date of grant. The fair values of the 2020 target FCF performance-based DSUs at the grant date assuming achievement of the highest level of performance (as required to be disclosed by the SEC), which assumes actual adjusted free cash flow for 2020 at or above 125% of the Company's 2020 internal financial plan, are as follows: $4,124,955 for Mr. Mahoney's award, $937,470 for Mr. Brennan's award, $937,470 for Mr. Fitzgerald's award, $562,457 for Mr. Mackey's award, and $712,462 for Mr. Mirviss.
		We value service-based DSUs based on the closing price of shares of our common stock on the date of grant.
		For more information regarding the stock awards we granted in 2020, please see the Grants of Plan-Based Awards table. For a more detailed description of the assumptions used in determining grant date fair values of DSUs granted in 2020, please see Note L — Stock Ownership Plans to our 2020 consolidated financial statements included in Item 8 of our Annual Report on Form 10-K for the year ended December 31, 2020.
(3)		The amounts included in the "Option Awards" column represent the aggregate grant date fair value of all stock options granted during each of 2020, 2019 and 2018 under our 2011 LTIP, as effective on the respective date of grant. These values have been determined in accordance with FASB ASC Topic 718. For a description of the assumptions used for purposes of determining grant date fair value of stock options granted in 2020, please see Note L — Stock Ownership Plans to our 2020 consolidated financial statements included in Item 8 of our Annual Report on Form 10-K for the year ended December 31, 2020. For more information regarding the stock option awards we granted in 2020, please see the Grants of Plan-Based Awards table.
(4)		Amounts in the "Non-Equity Incentive Plan Compensation" column represent cash awards made under our Annual Bonus Plan to our NEOs paid in February of the following year. Such amounts may be deferred under the Deferred Bonus Plan.
		For further information regarding the 2020 Annual Bonus Plan awards, please see the Compensation Discussion & Analysis section titled "Short-Term Incentives," the narrative to this table, and "Nonqualified Deferred Compensation".
(5)		The amounts shown in the "Change in Pension Value and Nonqualified Deferred Compensation Earnings" column reflect the change in the actuarial present value of the accumulated benefit under our Executive Retirement Plan for each retirement plan measurement date used for financial statement reporting purposes with respect to the Company's audited financial statements as compared to the prior retirement plan measurement date.
		Please see the narrative and related footnotes to the table in the section titled "Defined Benefit Retirement Plan" for more information regarding the accrued benefits for each NEO under this plan. No amount is included with respect to nonqualified deferred compensation earnings because there were no above-market or preferential earnings on nonqualified deferred compensation.


(a)		The amounts shown in this column represent matching contributions made by the Company for each NEO under our 401(k) Retirement Savings Plan. All individual and matching contributions to the 401(k) Retirement Savings Plan are fully vested upon contribution.
(b)		Pursuant to Mr. Mahoney's offer letter, he is permitted reasonable personal use of our corporate aircraft up to $100,000 per year in aggregate incremental cost to us, but he is not entitled to reimbursement by us for any taxes resulting from imputed income attributable to his personal use of the corporate aircraft. In light of the fact that Mr. Mahoney's travel plans are subject to change on short notice, the Company has agreed that he may use our corporate aircraft in connection with his service on the board of directors of Baxter International, Inc. so long as he fully reimburses us for the incremental costs associated with such travel or such costs are counted against his annual personal use amount.
		The amount reflected in the "Aircraft" column represents the aggregate incremental costs to us for personal use by the NEO of our corporate aircraft, as well as any incremental costs associated with persons accompanying such officer on business travel. We calculate the incremental cost to us by dividing the total annual variable operating costs for the corporate aircraft by the number of in-flight hours during the year. The resulting dollar per hour amount is then multiplied by the number of hours flown for personal use by the executive officer during the year, including the "dead head" costs of flying the aircraft to and from locations for personal use. Our corporate aircrafts are used predominantly for business travel. We do not include the fixed operating costs, such as pilot salary, general taxes and insurance, in the incremental cost calculation. The incremental cost does not include amounts attributable to the NEO for increased income taxes we incurred in 2020 as a result of disallowed deductions related to personal use under Internal Revenue Service rules. For 2020, the reflected amounts exclude $218,784 and $15,045 of disallowed corporate income tax deductions attributable to the personal use of the corporate aircraft during the year by Messrs. Mahoney and Brennan, respectively. Messrs. Mahoney and Brennan were taxed on the imputed income attributable to their respective personal use of the corporate aircraft and did not receive tax assistance from the Company with respect to this amount.
(c)		Amounts in the "Term Life Insurance" column consist of premiums and the imputed income for Company-paid term life insurance attributable to our NEOs. For Messrs. Mahoney, Brennan, Fitzgerald, Mackey, and Mirviss, the premium paid was $792, $537, $545, $477, and $455 respectively.
(d)		Amounts in the "Financial Planning" column reflect fees paid to a service provider for financial planning. In November 2019, our Compensation Committee approved a financial planning perquisite for our executive officers, including our NEOs. The program provides financial counseling and planning, investment and retirement management, insurance planning, and income tax planning and preparation services through a single service provider for US-based executive officers. Executive officers located outside of the United States will be eligible for reimbursement. In approving the program, the Compensation Committee considered the overall cost of the benefit (up to $12,000 per participant), prevalence of the benefit in the market, and benefit to the Company of reducing potential distraction to executive officers of complex personal financial situations.
(e)		Amounts in the "Other" column consist of the costs of miscellaneous gifts/prizes and annual physical examinations, where applicable.

The table below presents information regarding awards under the Company's 2020 Annual Bonus Plan and 2011 LTIP, including those pursuant to the Company's 2020 Performance Share Programs, during the year ended December 31, 2020. For a description of material factors helpful for an understanding of the information in the table below, please see the Compensation Discussion & Analysis and the narrative to this table.

									All Other Stock Awards: Number of Shares of Stock or Units (#)(4)

												Grant Date Fair Value of Stock and Option Awards ($)(5)
										All Other Option Awards: Number of Securities Underlying Options (#)(4)	Exercise or Base Price of Option Awards ($/Sh)
			Estimated Future Payouts under Non-Equity Incentive Plan Awards(1)			Estimated Future Payouts under Equity Incentive Plan Awards(2)
Name	Grant Date(3)	Date Approved	Threshold ($)	Target ($)	Maximum ($)	Threshold (#)	Target (#)	Maximum (#)

Michael F. Mahoney			0	1,980,000	4,455,000
	2/18/2020(6)	2/12/2020				26,090	65,227	130,454				2,895,427
	2/18/2020(7)	2/12/2020				16,306	65,227	97,840				2,749,970
	2/18/2020(8)	2/12/2020							65,227			2,749,970
	2/18/2020(8)	2/12/2020								243,362	$42.16	2,749,991
Daniel J. Brennan			0	578,040	1,300,590
	2/18/2020(6)	2/12/2020				5,929	14,824	29,648				658,037
	2/18/2020(7)	2/12/2020				3,706	14,824	22,236				624,980
	2/18/2020(8)	2/12/2020							14,824			624,980
	2/18/2020(8)	2/12/2020								55,309	$42.16	624,992
Joseph M. Fitzgerald			0	552,013	1,242,029
	2/18/2020(6)	2/12/2020				5,929	14,824	29,648				658,037
	2/18/2020(7)	2/12/2020				3,706	14,824	22,236				624,980
	2/18/2020(8)	2/12/2020							14,824			624,980
	2/18/2020(8)	2/12/2020								55,309	$42.16	624,992
	7/1/2020(9)	6/7/2020								116,959	$35.28	999,999
Edward F. Mackey			0	453,768	1,020,977
	2/18/2020(6)	2/12/2020				3,557	8,894	17,788				394,805
	2/18/2020(7)	2/12/2020				2,223	8,894	13,341				374,971
	2/18/2020(8)	2/12/2020							8,894			374,971
	2/18/2020(10)	2/12/2020							23,719			999,993
	2/18/2020(8)	2/12/2020								33,185	$42.16	374,991
Jeffrey B. Mirviss			0	406,004	913,510
	2/18/2020(6)	2/12/2020				4,506	11,266	22,532				500,098
	2/18/2020(7)	2/12/2020				2,816	11,266	16,899				474,975
	2/18/2020(8)	2/12/2020							11,266			474,975
	2/18/2020(8)	2/12/2020								42,035	$42.16	474,996


(1)		The amounts in these columns reflect target and maximum payouts under the 2020 Annual Bonus Plan. There is no threshold-level payout under the 2020 Annual Bonus Plan. The maximum possible payout under the 2020 Annual Bonus Plan is 225% of the target payout, representing the product of (i) a maximum of 150% of the target payout based on Company performance metrics and (ii) a maximum of 150% of the target payout based on individual performance objectives. The actual amount earned by each NEO under the 2020 Annual Bonus Plan is reported under the "Non-Equity Incentive Plan Compensation" column in the Summary Compensation Table. For additional information about our 2020 Annual Bonus Plan and a discussion of how these amounts are determined, please see the Compensation Discussion & Analysis section titled "Short-Term Incentives" and the section titled "2020 Annual Bonus Plan" in the narrative to this table.
(2)		The amounts in these columns reflect threshold, target and maximum share issuance under our 2020 Total Shareholder Return Performance Share Program (2020 TSR PSP) and 2020 Free Cash Flow Performance Share Program (2020 FCF PSP). The target performance-based DSUs awarded under these programs were granted to our NEOs in February 2020 as part of our annual review process and were awarded under our 2011 LTIP, as effective on the date of grant. For additional details regarding the awards to our NEOs pursuant to our 2020 TSR PSP and 2020 FCF PSP, please see footnotes 5 and 6 to this Grants of Plan-Based Awards table, respectively.
(3)		The Compensation Committee took action to grant the awards in this table on February 12, 2020, and determined that the awards should be granted as of February 18, 2020.
(4)		The amounts in these columns reflect the number of service-based DSUs and stock options granted to our NEOs under our 2011 LTIP as effective on the date of grant during 2020.


(5)		The amounts in this column have been determined in accordance with FASB ASC Topic 718. See footnotes 2 and 3 to the Summary Compensation Table for a description of the assumptions used in determining the grant date fair value of these awards.
(6)		These awards were granted pursuant to our 2020 TSR PSP. The threshold award level represents the minimum share issuance for each award that a participant may receive based on performance, which is 40% of the target TSR performance-based DSUs awarded under the program. The maximum share issuance for each award is 200% of the target TSR performance-based DSUs awarded under the 2020 TSR PSP. For additional information about our 2020 TSR PSP and a discussion of how these amounts are determined, please see the section titled "2020 Total Shareholder Return Performance Share Program" in the narrative to this table.
(7)		These awards were granted pursuant to our 2020 FCF PSP. The threshold award level represents the minimum share issuance for each award that a participant may receive based on performance, which is 25% of the target FCF performance-based DSUs awarded under the program. The maximum share issuance for each award is 150% of the target FCF performance-based DSUs awarded under the 2020 FCF PSP. For additional information about our 2020 FCF PSP and a discussion of how these amounts are determined, please see the section titled "2020 Free Cash Flow Performance Share Program" in the narrative to this table.
(8)		These awards were granted as part of our annual review process and awarded under our 2011 LTIP, as effective on the respective date of grant.
(9)		In connection with Mr. Fitzgerald's offer of employment as the Executive Vice President and President, Interventional Cardiology, Mr. Fitzgerald was granted an equity incentive award in the form of non-qualified stock options, vesting in one single installment on January 1, 2023.
(10)		This award was granted to Mr. Mackey under our 2011 LTIP, as effective on the date of grant, for retention purposes. The award will vest in one single installment, on the second anniversary date of the grant.

The following provides information about the terms of our 2020 Annual Bonus Plan, 2020 Performance Share Programs and our 2011 LTIP, pursuant to which our NEOs were awarded short- and long-term incentive compensation, as applicable and detailed in the tables above. For additional information regarding the application of these plans and programs to our NEOs in 2020, please see the Compensation Discussion & Analysis.

Our 2020 Annual Bonus Plan is administered by our Compensation Committee. The plan year for our 2020 Annual Bonus Plan ran from January 1, 2020 to December 31, 2020. Generally, all U.S. salaried employees not eligible for commissions under sales compensation plans and certain international employees selected for participation were eligible to participate in our 2020 Annual Bonus Plan, provided they had at least two full months of service during the plan year. Participants generally must be employed with us on the date payments are made in order to receive awards under the plan. However, in the event of death or retirement or certain involuntary terminations without cause, in each case, as described in the 2020 Annual Bonus Plan, participants may receive their performance incentive awards for the year on a prorated basis based on the percentage of the year the participant was employed by us and eligible to participate. Participants who have at least two months of eligibility, but less than a full year, similarly may receive awards under the 2020 Annual Bonus Plan on a prorated basis.

Each participant is provided with a target incentive award opportunity under the 2020 Annual Bonus Plan expressed as a percentage of his or her base salary. For a discussion of the 2020 target incentive award opportunities for our NEOs, please see the Compensation Discussion & Analysis sections titled "Individual Target Incentive Award Opportunity" and "2020 Annual Bonus Plan Awards Paid to Our NEOs."

Company Performance Metrics and Weighting. Under the 2020 Annual Bonus Plan, after year-end, a single Company-wide annual bonus pool (Total Bonus Pool) is funded based on the Company's performance measured against important Company-level financial performance metric targets. For 2020, our Compensation Committee selected adjusted EPS and adjusted net sales as our Company-level performance metrics. Each metric has a 50% weighting.

Company Metrics Defined. For purposes of our 2020 Annual Bonus Plan: (i) adjusted EPS equals adjusted net income (loss) divided by weighted average shares outstanding for the performance year (adjusted net income (loss) equals GAAP net income (loss) excluding certain charges (credits) from GAAP net income, including, but not limited to, amortization expense, goodwill and intangible asset impairment charges, acquisition- and divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), litigation-related net charges (credits), certain investment impairment losses (gains), EU Medical Device Regulation implementation charges, pension termination charges, and discrete tax items); and (ii) adjusted net sales is calculated at an assumed standard constant currency basis that excludes the impact of foreign currency fluctuations, which are highly variable and difficult to predict, and other adjustments.

For a discussion of the Company level targets under the 2020 Annual Bonus Plan, funding of the Total Bonus Pool and the individual performance component of the 2020 Annual Bonus Plan, and the impact of COVID-19 on the program, please see the Compensation Discussion & Analysis section titled "Short-Term Incentives."

Our 2020 Annual Bonus Plan provides that, to the extent permitted by applicable law, our Board will seek reimbursement of incentive compensation paid to any executive officer under the plan in the event of a restatement of our financial results that reduced a previously granted award's size or payment. Under such circumstances, and to the extent permitted by applicable law, we would seek to recover the amount of the 2020 Annual Bonus Plan award paid to such executive that was in excess of the amount that would have been paid based on the restated financial results. Additionally, our 2020 Annual Bonus Plan provides that to the extent permitted by applicable law, our Board may seek reimbursement of incentive compensation paid to an executive under the plan in the event of executive misconduct or gross dereliction of duty that resulted in a material violation of Company policy and caused significant harm to the Company. In such an event, and to the extent permitted by applicable law, the Board may seek reimbursement of all or a portion of cash incentive compensation awards paid within a certain time period under the plan.

Our 2020 TSR PSP is administered under our 2011 LTIP, as effective at the time of grant of performance-based DSUs under the program. The TSR performance-based DSUs awarded under the TSR PSP vest upon the satisfaction of both the Company performance criteria and service criteria under the 2020 TSR PSP, subject to acceleration in the event of certain qualifying terminations discussed below. Our executives, including our NEOs, are eligible to participate in the 2020 TSR PSP, which is administered by our Compensation Committee. For a discussion of the TSR performance-based DSUs awarded to our NEOs in 2020, please see the Compensation Discussion & Analysis section titled "2020 Long-Term Incentive Awards for our NEOs."

For a discussion of the Company performance criteria under the 2020 TSR PSP, please see the Compensation Discussion & Analysis section titled "2020 Long-Term Incentive Awards for our NEOs."

Calculation of TSR and Percentile Performance. The TSR for the Company and each other company in the S&P 500 Healthcare Index for the three-year performance period is determined based on the following formula:

The change in stock price is determined by subtracting the beginning stock price (the daily average closing price of one share of common stock for the two calendar months prior to the beginning of the performance period) from the ending stock price (the daily average closing price of one share of common stock for the last two calendar months of the performance period). The dividends paid are the total of all cash dividends paid on one share of common stock during the performance period.

Following the calculation of the TSR for the three-year performance period for our Company and each of the other companies in the S&P 500 Healthcare Index, the companies will be ranked in order of maximum to minimum TSRs for the full three-year performance period. Our percentile performance will be determined by (i) dividing (a) our ranking versus that of the other companies in the S&P 500 Healthcare Index minus one, by (b) the total number of companies in the S&P 500 Healthcare Index minus one, and (ii) subtracting the result from one.

Generally under the 2020 TSR PSP, except with respect to termination of employment due to retirement, death or disability, or in connection with a change in control, in each case, as described in the 2020 TSR PSP and/or the 2011 LTIP, a participant must be employed with us on December 31, 2022 to be eligible to receive shares of our common stock in respect of his or her TSR performance-based DSUs as to which the performance criteria under the program have been satisfied.

For information regarding potential payments upon certain terminations of employment or in connection with a change in control, please see "Potential Payments Upon Termination or Change in Control."

Our 2020 FCF PSP is administered under our 2011 LTIP, as effective at the time of grant of performance-based DSUs under the program. The 2020 grants of FCF performance-based DSUs vest

upon the satisfaction of both the one-year Company performance criteria and the three-year service criteria (inclusive of the performance period) under the 2020 FCF PSP, subject to acceleration in the event of certain qualifying terminations discussed below. Our executives, including our NEOs, were eligible to participate under the 2020 FCF PSP, which is administered by our Compensation Committee. For a discussion of the 2020 FCF performance-based DSUs awarded to our NEOs and the Company's achievement of the Company performance criteria under the program, please see the Compensation Discussion & Analysis section titled "2020 Long-Term Incentive Awards for our NEOs."

For a discussion of the Company performance criteria under the 2020 FCF PSP, please see the Compensation Discussion & Analysis sections titled "Long-Term Incentives" and "2020 Long-Term Incentive Awards for our NEOs."

Generally under the 2020 FCF PSP, except with respect to termination of employment due to retirement, death or disability, or in connection with a change in control, in each case, as described in the 2020 FCF PSP and/or the 2011 LTIP, a participant must be employed with us on December 31, 2022 to be eligible to receive shares of our common stock in respect of his or her 2020 FCF performance-based DSUs as to which the performance criteria under the program have been satisfied.

Employees, directors and other individuals who provide services to us and our affiliates who, in the opinion of the Compensation Committee, are in a position to make a significant contribution to our success or that of our affiliates are eligible for Awards under our 2011 LTIP. An amendment and restatement of the 2011 LTIP was approved by our stockholders at the 2020 Annual Meeting of Stockholders and became effective on October 1, 2020. Among other things, the amendment and restatement extended the Company's ability to continue to grant awards beyond March 1, 2021, the expiration date of the 2011 LTIP as previously in effect, and to increase to the number of shares of our common stock available for issuance under the plan.

The purpose of the broad-based equity incentive award opportunities available for grant under our 2011 LTIP is to attract, retain, engage and focus key employees and other eligible participants on achieving long-term stockholder value by rewarding them for the increased performance of our common stock underlying such awards. Our 2011 LTIP is administered by our Compensation Committee and provides for the grant of restricted or unrestricted common stock, restricted stock units (for awards granted prior to October 2020, referred to as "deferred stock units"), options to acquire our common stock, and stock appreciation rights (SARs), including types of awards subject to attainment of performance conditions (collectively, Awards). Our 2011 LTIP prohibits repricing or replacement of options or SARs and the issuance of in-the-money options or SARs, and includes limitations on the amounts of grants and payments to any individual within a given year as well as certain other customary limitations.

Generally, the deferred stock units granted in 2018 to our executives, including our NEOs, vest in five equal annual installments or, beginning in 2019, four equal annual installments, in each case from the

first anniversary of the date of grant, subject to continued service on each applicable vesting date. Generally, stock options vest in four equal annual installments, subject to continued service on each applicable vesting date, and expire on the tenth anniversary of the date of grant.

Generally, except with respect to termination of employment due to retirement, death or disability, or in connection with a change in control, in each case, as described therein or as otherwise provided for in the applicable award agreement, all equity awards terminate to the extent not vested immediately prior to the cessation of employment, and to the extent vested but not exercised at such time, remain exercisable for the lesser of one year or until the expiration of the stated term of the award. Further, in the event of a termination for "cause" (defined as conviction of, or a failure to contest prosecution for, a felony, or misconduct or dishonesty that is harmful to our business or reputation), or as a result of reasons that cast such discredit on the individual as to justify immediate termination of the award, in each case, as determined in the Compensation Committee's sole discretion, all outstanding equity awards (including unexercised stock options, whether vested or unvested) terminate immediately upon notice of such termination.

For a discussion of our plans and arrangements under which a change in control and/or termination of employment triggers payments or benefits, including our 2011 LTIP, please see the narrative to the tables appearing in "Potential Payments Upon Termination or Change in Control." Potential payments to our NEOs in 2020 under such plans or arrangements are included in the tables appearing in "Potential Payments Upon Termination or Change in Control."

With respect to our executives, including our NEOs, our Compensation Committee set the mix of equity award opportunities under our 2020 Long-Term Incentive Program at 25% target TSR performance-based DSUs, 25% target FCF performance-based DSUs, 25% stock options and 25% service-based DSUs. The service-based deferred stock units granted in 2020 vest in four equal annual installments beginning on the first anniversary of the date of grant, subject to continued service on each applicable vesting date and except as set forth under "Certain Separations from Service." For a discussion of the 2020 equity awards made to our NEOs, please see the Compensation Discussion & Analysis section titled "Long-Term Incentives."

The following table provides information with respect to outstanding unexercised non-qualified stock options and unvested deferred stock units for each NEO as of December 31, 2020.

	Option Awards					Stock Awards

Name	Grant Date	Number of Securities Underlying Unexercised Options (#) Exercisable(1)	Number of Securities Underlying Unexercised Options (#) Unexercisable(1)	Option Exercise Price ($)	Option Expiration Date	Number of Shares or Units of Stock That Have Not Vested (#)(2)	Market Value of Shares or Units of Stock that Have Not Vested ($)(3)	Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#)	Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($)(3)

Michael F. Mahoney	2/27/2012	674,941	0	6.28	2/27/2022
	2/28/2013	660,536	0	7.39	2/28/2023
	2/24/2014	346,083	0	13.08	2/24/2024
	2/23/2015	334,051	0	16.31	2/23/2025
	2/22/2016	337,268	0	17.26	2/22/2026
	2/28/2017	222,331	74,111	24.55	2/28/2027
	2/15/2018	139,042	139,044	27.09	2/15/2028
	2/21/2019	54,479	163,438	40.12	2/21/2029
	2/18/2020	0	243,362	42.16	2/18/2030
	2/22/2016					23,175	833,141
	2/28/2017					36,660	1,317,927
	2/15/2018					55,371	1,990,587
	2/15/2018					108,797(4)	3,911,252
	2/15/2018					71,981(5)	2,587,717
	2/21/2019					50,474	1,814,540
	2/21/2019					60,635(6)	2,179,828
	2/18/2020					65,227	2,344,911
	2/18/2020					57,791(7)	2,077,586


Filed by the Registrant ý
Filed by a Party other than the Registrant o
Check the appropriate box:
o		Preliminary Proxy Statement
o		Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
ý		Definitive Proxy Statement
o		Definitive Additional Materials
o		Soliciting Material under §240.14a-12


Nelda J. Connors		Independent Director
Founder, Chairwoman and Chief Executive Officer of Pine Grove Holdings, LLC
	Director Since: December 2009 Age: 55 Committees: Executive Compensation and Human Resources; Risk	Other Public Company Boards: Baker Hughes; BorgWarner Inc.; EnerSys Inc. Education: University of Dayton, B.S. and M.S. in Mechanical Engineering


Charles J. Dockendorff		Independent Director
Former Executive Vice President and Chief Financial Officer of Covidien plc
	Director Since: April 2015 Age: 66 Committees: Audit (Chair, Financial Expert); Risk	Other Public Company Boards: Haemonetics Corporation; Hologic, Inc.; Keysight Technologies, Inc. Education: University of Massachusetts at Amherst, B.B.A. in Accounting; Bentley College, M.S. in Finance


Yoshiaki Fujimori		Independent Director
Senior Executive Advisor of Japan to CVC Capital Partners
	Director Since: July 2016 Age: 69 Committees: Risk	Other Public Company Boards: Oracle Corporation Japan; Takeda Pharmaceutical Company; Toshiba Corporation; Shiseido Company, Limited Education: Tokyo University of Science, B.A. in Petroleum Engineering; Carnegie Mellon Graduate School of Business, M.B.A.


Donna A. James		Independent Director
Founder, President and Managing Director of Lardon & Associates LLC
	Director Since: July 2015 Age: 63 Committees: Executive Compensation and Human Resources (Chair); Nominating and Governance	Other Public Company Boards: L Brands, Inc.; The Hartford Education: North Carolina A&T State University, B.S. in Accounting


Information About the Annual Meeting and Voting			1
Internet Availability of Proxy Materials			9
Cautionary Statement Regarding Forward-Looking and Other Statements			9
Proposal 1: Election of Directors			10
Corporate Governance			17
Meetings and Board Committees			26
Director Compensation			32
Executive Officers			37
Certain Beneficial Ownership Matters			43
Compensation Discussion & Analysis			46
Risk Assessment of our Compensation Programs			75
Compensation Committee Report			75
Executive Compensation			76
Proposal 2: Advisory Vote to Approve Named Executive Officer Compensation			104
Equity Compensation Plans			107
Audit Committee Report			108
Proposal 3: Ratification of Appointment of Independent Registered Public Accounting Firm			109
Proposal 4: Stockholder Proposal			111
Stockholder Proposals and Company Information			115
Other Information			117
Annex A — Reconciliations of GAAP Financial Measures to Non-GAAP Financial Measures Used as Performance Metrics Under Certain of Our Short- and Long-Term Incentive Compensation Plans and Programs			A-1


Edward J. Ludwig		Independent Director
Former Chairman of the Board and Chief Executive Officer of Becton, Dickinson and Company
	Director Since: March 2014 Age: 69 Committees: Executive Compensation and Human Resources	Other Public Company Boards: CVS Health Corporation Education: The College of the Holy Cross, B.A. in Economics and Accounting; Columbia University, M.B.A.


Michael F. Mahoney		CEO, Chairman of the Board
President and Chief Executive Officer of Boston Scientific Corporation
	Director Since: November 2012 Age: 56	Other Public Company Boards: Baxter International, Inc. Education: University of Iowa, B.B.A. in Finance; Wake Forest University, M.B.A.


David J. Roux		Independent Director
Co-founder and co-managing partner of BayPine Capital
	Director Since: January 2014 Age: 64 Committees: Audit; Nominating and Governance (Chair)	Other Public Company Boards: None Education: Harvard College; Harvard University, M.B.A.; King's College, Cambridge University, M. Phil.


John E. Sununu		Independent Director
Former United States Senator from New Hampshire
	Director Since: April 2009 Age: 56 Committees: Audit (Financial Expert); Risk (Chair)	Other Public Company Boards: BlueRiver Acquisition Corp. Education: Massachusetts Institute of Technology, B.S. and M.S. in Mechanical Engineering; Harvard University, M.B.A.


Ellen M. Zane		Independent Director
CEO Emeritus at Tufts Medical Center and Tufts Children's Hospital
	Director Since: April 2016 Age: 69 Committees: Audit (Financial Expert); Nominating and Governance	Other Public Company Boards: Brooks Automation; Haemonetics Corporation; Synchrony Financial Education: George Washington University, B.A.; Catholic University of America, M.A. in Audiology and Speech-Language Pathology


(4)		Each non-employee director elected at our 2020 Annual Meeting of Stockholders was granted an equity award with a value of $185,000. For each director that elected to receive restricted stock, the restricted stock vests on the date of the annual meeting of stockholders immediately following the date of grant, subject to the director's continued service during such term. For each director that elected to receive deferred stock units, the deferred stock units vest on the date of the annual meeting of stockholders immediately following the date of grant, subject to continued service during such term, and vested shares of stock will be issued to the director upon his or her separation from Board service in accordance with the 2014 Non-Employee Director Deferred Compensation Plan.


		The annual equity awards to our directors during 2020 are shown below:


		The outstanding Restricted Stock, Restricted Stock Deferred and Deferred Stock Units held by the non-employee directors at December 31, 2020 are shown below:

Name	Outstanding Restricted Stock	Outstanding Deferred Stock Units and Restricted Stock Deferred


Nelda J. Connors	5,000	77,569
Charles J. Dockendorff	5,000	–
Yoshiaki Fujimori	–	23,111
Donna A. James	–	18,484
Edward J. Ludwig	–	32,673
Stephen P. MacMillan	7,052	45,694
David J. Roux	5,000	–
John E. Sununu	5,000	81,757
Ellen M. Zane	5,000	–


		For more information on the beneficial ownership of our directors, please see the section titled "Certain Beneficial Ownership Matters".


(5)		The outstanding, unexercised stock options at December 31, 2020, pursuant to stock option awards previously granted to non-employee directors, all of which have vested, are shown below.


(6)		The amounts in this column represent the "above-market" portion of 2020 earnings under the interest crediting investment option available under the Non-Employee Director Deferred Compensation Plan. The interest rate used under the plan each year is the Moody's Composite Yield on Seasoned Corporate Bonds for the month of September of the preceding year. For 2020, the interest rate used under the plan was 3.38%, the Moody's rate in September 2019. Under SEC rules, interest on non-qualified deferred compensation is considered "above-market" if the interest rate exceeds 120% of the federal long-term interest rate, with compounding at the rate that corresponds most closely to the rate under the plan, at the time the interest rate or formula is set. For 2020, 120% of the applicable federal long-term interest rate was 2.66%.

Name and Address			Percent of Shares Outstanding


BlackRock, Inc.	135,962,117	(1)	9.57%
55 East 52nd Street, New York, NY 10055
The Vanguard Group	110,781,158	(2)	7.80%
100 Vanguard Blvd., Malvern, PA 19355
Wellington Management Group LLP Wellington Group Holdings LLP Wellington Investment Advisors Holdings LLP	77,265,641	(3)	5.44%
280 Congress Street, Boston, MA 02210


Reported Financial Performance Metrics		Adjusted Financial Performance Metrics
$9.913 billion		$9.955 billion
GAAP Net Sales		Adjusted Net Sales(1)(2) for Annual Bonus Plan
$(0.08)		$0.96
GAAP Net Loss Per Share		Adjusted Net Income Per Share(1) (Adjusted EPS) for Annual Bonus Plan
$1.508 million		$1.980 billion
GAAP Operating Cash Flow Provided by Operating Activities		Adjusted Free Cash Flow(1) for Free Cash Flow Performance Share Program
30.90% 3-year Total Shareholder Return(3) For Total Shareholder Return Performance Share Program


(1)		Revenue is for the trailing four quarters as of December 31, 2020 and total shareholder return is calculated as of December 31, 2020, unless otherwise noted. Market cap is calculated using the closing price of each company's common stock on December 31, 2020 multiplied by the number of outstanding shares of common stock as reported by the company in its most recent periodic report filed with the Securities and Exchange Commission.
(2)		Total shareholder return is calculated in accordance with the methodology described in the Executive Compensation section titled "2020 Total Shareholder Return Performance Share Program."
(3)		Agilent Technologies, Inc. market cap is provided as of January 31, 2021 and revenue is provided for the trailing four quarters as of January 31, 2021.
(4)		Medtronic plc market cap is provided as of January 29, 2021 and revenue is provided for the trailing four quarters as of January 29, 2021.

Name	2019 Base Salary	2020 Base Salary	% Increase


Michael F. Mahoney	$1,280,000	$1,320,000	3.1%
Daniel J. Brennan	$660,000	$680,000	3.0%
Joseph M. Fitzgerald	$670,000	$690,000	3.0%
Edward F. Mackey	$580,000	$605,000	4.3%
Jeffrey B. Mirviss	—	$580,000	—


(1)		In order to balance the uneven impact of the COVID-19 pandemic on our global businesses, regions, and functions, for purposes of the 2020 Annual Bonus Plan, all Participating Units were funded at the same level, as described in the section titled "Funded Total Bonus Pool Allocated to Participating Units."


(1)		Adjusted EPS and Adjusted Net Sales are non-GAAP financial measures. For a reconciliation of these non-GAAP measures to the most directly comparable GAAP measures and insight into how these non-GAAP measures are considered by management, please see the Executive Compensation section titled "Narrative Disclosure to Summary Compensation Table and Grants of Plan-Based Awards Table — 2020 Annual Bonus Plan" and Annex A.

Adjusted EPS (As a Percent of Target)		Total Bonus Pool Funding Range


<90%		50%
90% to <98%		50% to 90%
98% to <102%		90% to 115%
102% to <104%		115% to 135%
104%+		135% to 150%

Adjusted Net Sales (As a Percent to Target)		Total Bonus Pool Funding Range


<97%		50%
97% to <99%		50% to 90%
99% to <101%		90% to 115%
101% to <102%		115% to 135%
102%+		135% to 150%

	Individual Target Award Opportunity (As a % of Annual Base Salary)

Name	2019		2020

Michael F. Mahoney		150%	150%
Daniel J. Brennan		85%	85%
Joseph M. Fitzgerald		80%	80%
Edward F. Mackey		75%	75%
Jeffrey B. Mirviss		—	70%

Name	Individual Target Award Opportunity (As a % of Annual Base Salary)	2020 Target Award(1)	Participating Unit Performance Percentage(1)	Individual Performance Percentage	2020 Actual Bonus Plan Award(2)	Actual as % of Target(1)


Michael F. Mahoney	150%	$1,980,000	75%	100%	$1,485,000	75%
Daniel J. Brennan	85%	$578,000	75%	105%	$455,000	79%
Joseph M. Fitzgerald	80%	$552,000	75%	100%	$414,000	75%
Edward F. Mackey	75%	$454,000	75%	115%	$391,000	86%
Jeffrey B. Mirviss	70%	$406,000	75%	115%	$350,000	86%


(1)		Actual payouts are greater than the target payout percentage of 75% in cases where an NEO's Individual Performance Percentage is greater than 100%.
(2)		2020 Target and Actual Bonus Plan Awards are rounded to the nearest thousand.


(1)		Under our 2011 Long-Term Incentive Plan, these awards are called deferred stock units, or DSUs. Under our Amended and Restated 2011 Long-Term Incentive plan, which was effective October 1, 2020, these awards are called restricted stock units or RSUs. For purposes of this proxy statement, unless noted otherwise, we refer to these awards as DSUs, as the awards made to our NEOs from 2011 through 2020 were made under our 2011 LTIP.
(2)		We do not pay dividends on stock options, unvested Company performance-based DSUs or service-based DSUs.
(3)		Adjusted free cash flow is reported operating cash flow minus capital expenditures and excludes cash flows associated with certain significant and unusual litigation, acquisition, restructuring and tax-related items. For a reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure and insight into how this non-GAAP measure is considered by management, please see Annex A.

Grant Year	Performance Metric	Achievement	DSUs Earned


2018	TSR Percentile Performance Rank for the three-year period ended December 31, 2020	32^nd relative to that of the other 55 companies in the S&P 500 Healthcare Industry Index (43^rd percentile) 78% of target TSR performance based DSUs earned	Michael F. Mahoney — 71,981 DSUs Daniel J. Brennan — 16,195 DSUs Joseph M. Fitzgerald — 17,995 DSUs Edward F. Mackey — 10,796 DSUs Jeffrey B. Mirviss — 7,917 DSUs
2020	Adjusted FCF for the one-year period ended December 31, 2020	$1.980 billion or 94.3% of target(1) 88.6% of target FCF performance-based DSUs earned	Michael F. Mahoney — 57,791 DSUs Daniel J. Brennan — 13,134 DSUs Joseph M. Fitzgerald — 13,134 DSUs Edward F. Mackey — 7,880 DSUs Jeffrey B. Mirviss — 9,981 DSUs
			All DSUs earned pursuant to our 2020 FCF Performance Share Program are subject to continued service until December 31, 2022.


(1)		Adjusted free cash flow is not prepared in accordance with GAAP. For a reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure and insight into how this non-GAAP measure is considered by management, please see Annex A.


		We determined the grant date fair value of the 2020 TSR performance-based DSUs using a Monte Carlo simulation methodology, utilizing the following key assumptions:


Stock price on date of grant		$42.16
Risk-free rate		1.37%
Measurement period (in years)		2.87


(6)		The amounts shown for 2020 in the "All Other Compensation" column are comprised of the following components: